CONFIDENTIALITY STATEM ENT
 
The information being provided in this protocol is considered confidential, proprietary trade secret information as 
defined by the Federal Trade Secrets Acts and is thus prot ected from disclosure to unauthorized parties under the 
Freedom of Information Act. This protocol shall be considered a confidential document that provides information 
for the sole use of clinical Investigators for the referenced study, their teams, and the study site Institutional Review 
Board (IRB). 
Protocol Title A Randomized, Double-Blind, Placebo-Controlled, 
Parallel Group Study to Evaluate the Efficacy, Safety, 
Tolerability, Biomarkers and PK of ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome (ARDS) 
Protocol Number MN-166-COVID-19-201 
Investigational Product MN-166 (ibudilast) 
Indication Prevention of Acute Respiratory Distress Syndrome 
(ARDS) 
Sponsor MediciNova, Inc.
4275 Executive Square La Jolla, CA 92037 
Sponsor Signatory Kazuko Matsuda, MD PhD MPH 
Chief Medical Officer MediciNova, Inc. 
Date Original protocol dated 24 April 2020 
Amendment 1 protocol dated 18 June 2020 Amendment 2 protocol dated 03 November 2020 Amendment 3 protocol dated 18 February 2021 Amendment 4 protocol dated 31 March 2021 
MediciNova, Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential 
Page 2 of 44 
 1.0 STATEMENT OF COMPLIANCE 
This study will be conducted in accordance w ith International Conference on Harmonization 
Good Clinical Practice (ICH  GCP), applicable United States (U .S.) Code of Federal Regulations 
(CFR), applicable country and local regulations  and in accordance with the ethical principles 
outlined in the Declaration of Helsinki. The Princi pal Investigator will assure that no changes to 
the protocol will take place without prior agr eement from the Investigational New Drug (IND) 
sponsor and documented approval from the Inst itutional Review Boar d (IRB), except where 
necessary to eliminate an immediate h azard(s) to the trial participant.  
The protocol and informed consent form will be submitted to the IRB for review and approval. Approval of both the protocol and the consent form  must be obtained before any participant is 
enrolled. 
MediciNova, Inc 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 3  of 44 
 2.0 INVESTIGATOR AGREEMENT 
 
PROTOCOL:  MN-166-COVID-19-201 Amendment 4  
I have read the foregoing protocol and ag ree to conduct the study as described herein. 
By signing the protocol, the Inves tigator agrees to keep all in formation provided by MediciNova 
Inc. in strict confidence and to request the same  from his/her staff and the Institutional Review 
Board. Study documents provided by MediciNova Inc.  will be stored appropriately to ensure 
their confidentiality. The Investigator should not disclose such information to others without 
authorization, except to the extent  necessary to conduct the study.  
 
 _____________________________________________      ______________________________ 
Investigator (Print Name)                   Date 
 
 _____________________________________________ Investigator’s Signature         
 
MediciNova, Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential 
Page 4 of 44 
    
3.0 PROTOCOL SIGNATURE PAGE 
 
 Protocol: MN-166-COVID-19-201 Amendment 4  
 
MediciNova, Inc.          
                                           March 31, 2021 
_____________________________________________      _______________________ 
Kazuko Matsuda, M.D., Ph.D., M.P.H.       Date Chief Medical Officer 
 
  

MediciNova, Inc 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 5  of 44 
 4.0 TABLE OF CONTENTS 
1.0 STATEMENT OF COMPLIANCE ...........................................................................................2  
2.0 INVESTIGATOR AGREEMENT.............................................................................................3  
3.0 PROTOCOL SIGNATURE PAGE ...........................................................................................4  
4.0 TABLE OF CONTENTS ......................................................................................................... ..5 
5.0 LIST OF ABBREVIATIONS ....................................................................................................9  
6.0 SYNOPSIS ...............................................................................................................................12  
7.0 SCHEDULE OF ASSESSMENTS ..........................................................................................17  
8.0 BACKGROUND .....................................................................................................................19  
8.1 Acute Respiratory Distress Syndrome (ARDS) .......................................................................19  
8.2 MN-166 (ibudilast) ..................................................................................................................19  
8.3 Clinical Pharmacology ..................................................................................................... ........20  
8.4 Rationale for Use of Ibudila st for prevention of ARDS ..........................................................20  
8.5 MIF Inhibition and ARDS ................................................................................................... ....20  
8.6 PDE4 Inhibition and ARDS .....................................................................................................21  
8.7 ARDS animal model study with Ibudilast ...............................................................................21  
8.8 Previous Human Experience ....................................................................................................21  
9.0 CLINICAL OVERVIEW.........................................................................................................22  
9.1 MediciNova-Sponsored Studies...............................................................................................22  
9.2 Study Dose Justification .................................................................................................. ........23  
9.3 Treatment Duration Justification .......................................................................................... ...23  
10.0 TRIAL OBJECTIVES ...........................................................................................................24  
10.1 Primary Objectives ....................................................................................................... ..........24  
10.2 Secondary Objectives.............................................................................................................24  
11.0 OVERALL STUDY DESIGN ...............................................................................................24  
11.1 Screening................................................................................................................................24  
11.2 Treatment Phase .....................................................................................................................25  
11.3 Follow-up ...............................................................................................................................25  
11.4 Early Termination/Discharge from Hospital .........................................................................25  
12.0 SELECTION OF SUBJECTS................................................................................................25  
12.1 Study Population ....................................................................................................................25  
MediciNova, Inc 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 6  of 44 
 12.2 Inclusion Criteria ...................................................................................................................26  
12.3 Exclusion Criteria ..................................................................................................................26  
12.4 Child-Pugh Scoring Table ................................................................................................. .....27  
12.5 Screen Failures .......................................................................................................... .............27  
12.6 Subject Withdrawal/Dis continuation Criteria ........................................................................27  
12.7 Subject Stopping Criteria .......................................................................................................28  
12.8 Study Stopping Criteria..........................................................................................................28  
13.0 TREATMENTS .....................................................................................................................29  
13.1 Study Drug Supply .................................................................................................................29  
13.2 Study Drug Packaging and Labeling .....................................................................................29  
13.3 Study Drug Storage ................................................................................................................30  
13.4 Study Drug Administration ................................................................................................ ....30  
13.5 Dose Interruptions ..................................................................................................................30  
13.6 Method of Assigning Subj ects to Treatment Groups .............................................................30  
13.7 Blinding..................................................................................................................................31  
13.8 Prohibited Medication ............................................................................................................31  
13.9 Treatment Compliance ..................................................................................................... ......31  
14.0 STUDY PROCEDURES .......................................................................................................31  
14.1 Informed Consent ...................................................................................................................31  
14.2 Clinical Lab Testing ...............................................................................................................31  
14.3 Biomarker Samples ........................................................................................................ ........32  
14.4 Pharmacokinetic (PK) Samples ............................................................................................. 32 
14.5 Clinical Assessment Scale ................................................................................................ .....32  
15.0 STUDY ASSESSMENTS .....................................................................................................33  
15.1 Screening................................................................................................................................33  
15.2 Randomization ............................................................................................................ ...........33  
15.3  Treatment Phase ..........................................................................................................33  
15.3.1 Day 1 (Baseline), Day 3, Day 5 and Day 7 .........................................................................33  
15.3.2 Day 2, Day 4, and Day 6 .....................................................................................................34  
15.3.3  Follow-up Phase (Day 14 Day 28 and Day 60) ..........................................................34  
15.3.4  Early Termination/Discharged from Hospital ............................................................35  
16.0 SAFETY ASSESSMENTS ....................................................................................................35  
MediciNova, Inc 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 7  of 44 
 16.1 Definition of Adverse Event ..................................................................................................36  
16.2 Assessment of Adverse Events ..............................................................................................36  
16.3 Severity Assessment ..............................................................................................................36  
16.4 Relationship to Study Drug ....................................................................................................37  
16.5 Recording Adverse Events ................................................................................................. ....37  
16.6 Treatment and Follow-Up of Adverse events (AEs) .............................................................38  
16.7 Serious Adverse Events (SAEs).............................................................................................38  
16.8 SAE Reporting Requirements ............................................................................................... .38 
17.0 GUIDANCE FOR OVERDOSE ............................................................................................39  
18.0 REPORTING AND FOLLOW-UP OF PREGNANCIES .....................................................39  
19.0 STATISTICAL CONSIDERATIONS...................................................................................40  
19.1 Analysis Population ...................................................................................................... .........40  
19.2 Primary Endpoints .................................................................................................................41  
19.3 Secondary Endpoints .............................................................................................................41  
19.4 Safety Analysis ......................................................................................................................41  
19.5 Pharmacokinetic Analysis ................................................................................................. .....42  
20.0 ETHICS..................................................................................................................................42  
20.1 Ethics Review ............................................................................................................ ............42  
20.2 Ethical Conduct of the Study ............................................................................................. ....42  
20.3 Written Informed Consent ................................................................................................. ....42  
20.4 Confidentiality .......................................................................................................................42  
21.0 REFERENCES ......................................................................................................................43  
  
 
 
 
 
 
  
MediciNova, Inc 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 8  of 44 
  
List of Tables 
Table 1 Schedule of Assessments ............................................................................................... ...17  
Table 2 Child-Pugh Scoring Table ................................................................................................27  
Table 3 Study Drug Information ................................................................................................ ....29  
Table 4 CMP, CBC, and Coagulation Tests ..................................................................................31  
Table 5 Adverse Events Severity Definitions ................................................................................36  
Table 6 Adverse Events Causality Definitions ..............................................................................37  
 
MediciNova, Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential 
Page 9 of 44 
  
5.0 LIST OF ABBREVIATIONS 
Abbreviation  Term 
AE adverse event 
ALI acute lung injury 
ALP alkaline phosphatase 
ALS amyotrophic lateral sclerosis 
ALT (SGPT) alanine aminotransferase 
ARDS acute respiratory distress syndrome 
AST (SGOT) aspartate aminotransferase 
AUC Area under the curve 
β-hCG  beta-subunit of human chorionic gonadotropin 
bid twice daily 
BiPAP Bilevel positive airway pressure 
BPD bronchopulmonary dysplasia 
BUN Blood urea nitrogen 
CBC Complete Blood Count 
CFR Code of Federal Regulations 
CIRB Central Institutional Review Board 
Cmax Maximum plasma concentration 
CMP Comprehensive Metabolic Panel 
CNS central nervous system 
COPD Chronic obstructive pulmonary disease 
COVID-19 coronavirus disease 2019 
CPAP Continuous positive airway pressure 
CRA clinical research associate 
CRF case report form 
CRO contract research organization 
CRP C-reactive protein 
CTCAE Common terminology criteria for adverse events 
CYP cytochrome 
DDI drug-drug interaction 
dL deciliter 
MediciNova, Inc 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 10  of 44 
 Abbreviation  Term 
ECMO extracorporeal membrane oxygenation 
eCRF electronic case report form 
FDA Food and Drug Administration 
FiO 2 fraction of oxygen in inspired air 
GCP Good Clinical Practice 
GGT gamma-glutamyl transferase 
GI gastrointestinal 
GOLD Global initiative for chronic obstructive lung disease 
HIPAA Health Insurance Portability and Accountability Act 
HV healthy volunteer 
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonization 
IEC Independent Ethics Committee 
IL-1β Interleukin-1 beta 
IL-6 Interleukin-6 
IND Investigational New Drug 
INR international normalized ratio 
IRB Institutional Review Board 
L liter 
LPS lipopolysaccharide 
MCP monocyte chemoattractant protein  
MedDRA Medical Dictionary for Regulatory Activities 
mg milligram 
MIF migration inhibitory factor 
MMP matrix metalloproteinase 
MS Multiple sclerosis 
ms milliseconds 
NIAID National Institute of Allergy and Infectious Diseases 
PaO 2 partial pressure of oxygen in arterial blood 
PCR polymerase chain reaction 
PDE phosphodiesterase 
PEEP Positive end-expiratory pressure 
MediciNova, Inc 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 11  of 44 
 Abbreviation  Term 
PI Principal Investigator 
PK pharmacokinetics 
PT prothrombin time 
PTT Partial thromboplastin time 
qd Once daily 
RA room air 
RR respiratory rate 
RRMS Relapsing-remitting MS  
RT-PCR reverse transcription polymerase chain reaction 
SAE serious adverse event 
SAP statistical analysis plan 
SARS-CoV-2  severe acute respiratory syndrome coronavirus 2 
SOPs standard operating procedures 
SpO 2 Peripheral capillary oxygen saturation 
SUSAR Suspected Unexpected Serious Adverse Reaction 
TB tuberculosis 
TEAE treatment-emergent adverse event 
TESAE treatment-emergent serious adverse event 
TNFα  tumor necrosis factor alpha  
TRAE treatment-related adverse event 
ULN Upper limit of normal 
WBC White blood cells 
WHO World Health Organization  
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 12  of 44 
  
6.0 SYNOPSIS 
 
Name of Investigational Product: MN-166 (ibudilast)  
Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to 
Evaluate the Efficacy, Safety, Tolerability, Biomar kers and PK of ibudilast (MN-166) in COVID-19 
Subjects at Risk for Developing Acute Respiratory Distress Syndrome (ARDS)  
Study Number: MN-166-COVID-19-201  
Study Phase: Phase 2  
Study Center:  Multicenter  
Number of Subjects (Planned): A pproximately 40 patients  
FPI Date: Anticipated 4Q2020  
Screening Phase: up to 3 days,  Treatment Phase: 7 days, Follow-up Phase: Study Day 14,  28, 
and Day 60  
Duration of Study Drug Treatment: 7 days  
Study Treatments 
Test Drug: Ibudilast (MN-166) oral 50 mg bid 
Comparator Drug: Matching placebo oral 50 mg bid Study drug administration: Study drug will be administrated or ally. If subject becomes dependent 
on a gastric tube, study drug can be given via gastric tube by opening the capsules in an enteral 
syringe, then suspend in 30 mL distilled water. 
If study drug is started on Day 1 in the PM, the last  dose of study drug will be taken on Day 8 in the 
AM. 
Duration of Subject Participation: Approximately 60 days  
Study Design: This is a randomized (1:1) double-blind, placebo-controlled, parallel-group study of 
ibudilast in hospitalized COVID-19 subjects at risk for developing ARDS receiving standard of care 
including anticoagulation. The study will consis t of a Screening Phase followed by a Treatment and 
Follow-up Phase. Following the Screening Phase, if th e subject meets eligibility criteria, subject will 
be administered treatment with MN-166 (ibudil ast) or placebo. Subjects will receive ibudilast 100 
mg/d (50 mg b.i.d) or placebo every day for 7 days.  Upon completion of the 7-day Treatment Phase, subject will be followed-up at Day 14 , Day 28 and Day 60 post baseline.  
Screening Phase (up to 3 days)  
The following screening assessments will be perform ed upon signing the ICF: inclusion/exclusion 
criteria review, physical examination, assess vital signs and O
2 use and SpO 2, clinical status using 
the NIAID scale, ECG, draw blood for plasma cytokines that include migration inhibitory factor 
(MIF), (interleukin 1-beta (IL-1 β), interleukin 6 (IL-6), tumor necrosis factor (TNF α), C-reactive 
protein (CRP) and other exploratory biomarkers. Pharmacokinetic (PK) sa mples, complete blood 
count (CBC), comprehensive metabolic panel (CMP), D-dimer, and coagulation tests will also be 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 13  of 44 
 drawn. A serum pregnancy test will be done in non-menopausal females. The use of prior 
medications taken will be recorded for 7 days prior to Day 1.  
Treatment Phase (7 days)  
On Day 1 (Baseline) of the Treatment Phase, hosp italized subjects will be treated with MN-166 or 
placebo for a 7-day  period. S ubjects will undergo study-related procedures including physical 
examination, vital signs, clinical status assessment using the NIAID scale, O 2 use and SpO 2, ECG, 
blood collection of biomarkers, PK (except Day 7), CBC, CMP, D-dimer and coagulation and 
information on adverse events and conc omitant medications will be recorded. (see Table 1  Schedule 
of Events).  
Individual patient stopping criteria based on the know n safety profile of ibudilast and study stopping 
criteria will be implemented (see protocol sections 12.7  and 12.8). 
 
An independent medical safety monitor will eval uate safety on an ongoing basis during the study. 
After each of the first three subjects are dosed, th e medical safety monitor will review the data with 
the PI and sponsor and will make a recommendation to proceed/stop. After the first three subjects 
are evaluated, the medical safety monitor will con tinue to review safety data throughout the study.  
 
Follow-up Phase 
The Follow-up Phase consists of three visits, Day 14 (±  3 d), Day 28 (± 3 d) and Day 60 (± 7d).    
Day 14  On Day 14, site staff will conduct  physical examination, clinical status scale, vital signs and O
2 use, 
ECG, CBC, CMP, D-dimer, and coagulation tests, biomarkers, AE and conm ed review, and record 
survival status. If subject is no longer hospitalized, a telephone follow-up to record O 2 usage and 
SpO 2, survival, AEs and conmeds taken will be conducted.  
 
Day 28 (telephone follow-up if patient is no longer hospitalized)  
On Day 28, the following assessments will be performed in all subjects: clinical status, O 2 therapy 
status use, AE and conmed review, and survival status.  
. 
Day 60  
On Day 60, the following assessments will be performed in all subjects: clinical status, O 2 therapy 
status, survival status, and AE and conmed revi ew. In addition, vital signs, 12-lead ECG, and 
clinical safety labs (CBC, CMP, CRP, D-Dimer,  PT and INR) will be performed in intubated 
subjects only. 
Discharged prior to Study Day 7 
Subjects who are discharged prior to Day 7 will be given the remainder of their study medication to 
be taken at home twice daily a nd will be given a pulse oximeter to measure their oxygen levels once 
daily until Study Day 14.  
     
 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 14  of 44 
 Primary Efficacy Objectives  Primary Efficacy Endpoints 
To evaluate the efficacy of ibudilast vs. placebo 
in COVID-19 subjects measured by the 
proportion of subjects free of respiratory failure (i.e., decreased need for O
2 therapy)  • Proportion of subjects free from respiratory failure as defined by the 
need for decreased oxygen 
requirements (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Day 28  
• Incidence of mechanical ventilation 
/intubation at Day 28 
To evaluate the efficacy of ibudilast vs. placebo in COVID-19 subjects measured by clinical 
status (i.e., improvement on NIAID scale)  • Mean change from baseline in clinical status on NIAID 8-point ordinal scale at Day 28 
• Percentage of patients with at least a one-point improvement in clinical status using the NIAID 8-point ordinal scale at Day 28.  
• All-cause mortality at Day 28 
Secondary Efficacy Objectives  Secondary Efficacy Endpoints 
To evaluate the efficacy of ibudilast vs. placebo in COVID-19 subjects measured by the proportion of subjects free of respiratory failure (i.e., decreased need for O
2 therapy)  • Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirements (invasive mechanical ventilation, non-invasive ventilation, 
high-flow oxygen, or ECMO, CPAP, 
BiPAP, nasal cannula) at Days 7, 14, and Day 60  
• Incidence of mechanical ventilation /intubation at Day 7, Day 14, and Day 60  
• Incidence of ICU admission 
To evaluate the efficacy of ibudilast vs. placebo in COVID-19 subjects measured by clinical status (i.e., improvement on NIAID scale)  • Mean change from baseline in clinical status on NIAID 8-point ordinal scale at Day 7, Day 14, and Day 60  
• Percentage of patients with at least a one-point improvement in clinical status using the NIAID 8-point ordinal scale at Day 7, Day 14, and Day 60  All-cause mortality at Day 7, Day 14, and Day 60  
To evaluate the anti-inflammatory effects of ibudilast vs. placebo on cytokine levels  • Mean change from baseline in migration inhibitory factor (MIF), 
(interleukin 1-beta (IL-1 β), interleukin 
6 (IL-6), tumor necrosis factor alpha 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 15  of 44 
 (TNFα), and C-reactive protein (CRP) 
at Day 7  
Secondary Safety Objectives  Secondary Safety Endpoints 
To evaluate the safety and tolerability of 
ibudilast versus placebo  • Incidence, frequency and severity of treatment-emergent adverse events at Days 7, 14, 28, and 60  
• Mean change from baseline of the following parameters throughout the study at Days 7, 14, and 60 (in intubated subjects only): 
o ALT 
o AST 
o serum creatinine 
o BUN 
o complete blood count 
o total bilirubin 
o D-dimer 
To evaluate pharmacokinetics (PK) of ibudilast  • PK plasma concentrations of ibudilast  
 
Study Entry Criteria 
Inclusion Criteria: 
1. Written or verbal informed consent by subject or subject representative is obtained  
2. Male or female subjects age 18 to 80 years, inclusive 
3. SARS-CoV-2 infection confirmed with WHO criteria (including a positive PCR of any 
specimen, (e.g., blood, respiratory, stool, urine, or any other body fluid) 
4. Chest imaging (radiograph, CT scan or lung u ltrasound) with abnorma lities consistent with 
COVID-19 pneumonia 
5. SpO 2 ≤ 92% on room air (RA), RR ≥24 breaths per min on RA, and/or requirement for 
supplemental oxygen  
6. At least 1 risk factor which may put patient at higher risk for more severe illness from 
COVID-19: Age > 65, underlying serious hear t disease, chronic lung disease, moderate to 
severe asthma, body mass index of ≥ 40 or diabetes 
7. C-reactive protein >35 mg/L 
8. No known allergies to the study drug or its excipients 
Exclusion Criteria: 
1. Suspected active bacterial, fungal, viral or other cause of respiratory failure other than 
COVID-19 
2. Known or suspected immunosuppression with immunosuppressant medications or 
chemotherapeutic agents 
3. Active primary lung cancer or another metastatic malignancy to the lungs 
4. Moderate to severe liver failure (see section 12.4) defined by Child-Pugh score of ≥ 7 
measured by: 
• Total bilirubin 
• Serum albumin 
• INR 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 16  of 44 
 • Ascites 
• Hepatic encephalopathy 
5. The following abnormal laboratory tests if any of the criteria are met: 
• Platelet Count < 75,000 /mm3 
• White Blood Count < 2500 /mm3 
• ALT or AST or Total Bilirubin >3 x ULN 
• Bilirubin > 3 mg/dL 
• Serum albumin less than 28 g/L 
6. Subject is on dialysis 
7. On home ventilator support or  continuous domiciliary O 2 therapy for baseline lung disease  
8. Active tuberculosis (TB) infection 
9. Lactating or pregnant at Screening  
10. History of stomach or intestinal surgery or any other condition that could interfere with or is 
judged by the Investigator to interfere w ith absorption, distribution, metabolism, or  
excretion of study drug 
11. Treatment with an investigational drug or off-l abel medication within 5 half-lives or 30 days 
whichever is longer prior to study drug treatment 
12. Participating in another COVID-19 clinical trial   
13. Any other serious medical condition or abnorma lity that, in the Investigator’s opinion, 
would preclude participation in the study. 
Analysis Populations 
Full Analysis Set: All subjects who sign informed consent, are randomized, receive treatment and 
have at least one post dose efficacy assessment. Per Protocol Analysis: all randomized subjects who sufficiently complied with the protocol. Details 
of the evaluability criteria will be outlin ed in the statistical analysis plan. 
Statistical Methods 
Full details of the statistical methods including ha ndling of missing data and deaths will be outlined 
in the statistical analysis plan. Since this is an early proof of concept study, no formal sample size 
calculations have been performed.  
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 17  of 44 
 7.0 SCHEDULE OF ASSESSMENTS 
Table 1 Schedule of Assessments 
 Phase Screening Double-Blind Treatment Phase e,g  Follow-up 
Study Day 
 Day -3 Day 1  
BL Day 2 Day 3 Day 4 Day 5 Day 6 Day 7  
Day 14e 
(± 3)  
Day 28 
(+/-3) Day 60 
(+/- 7d)  
Informed consent X           
Inclusion/exclusion 
criteria review X           
 Brief physical exam  X X  X  X  X X   
Clinical status using 
NIAID scale X X X X X X X X X X X 
Vital signs (BP, RR,  HR, Temp) X X X X X X X X X  Xi 
O2 therapy status and 
SpO 2 X X X X X X X X X X X 
12-lead ECG X Xa  Xa  Xa  Xa   Xi 
Biomarker plasma 
samples: MIF, IL-1β , 
IL-6, TNF- α Xb X  
 X  X  X X   
PK blood samplec  X  X  X      
CBC, CMP, CRP,  
D-dimer, PT, INR  Xd X  X  X  X X  Xi 
Randomize f X            
Administer study drug  X h X X X X X X    
Adverse event review  X X X X X X X X X X 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 18  of 44 
  
 
 
      Prior/Concomitant 
medication review X X X X X X X X X X X 
Record survival status
j         X X X 
  a 12-lead ECG to be done between 2-4 hours after AM dose.   
b Biomarker blood sample collection at screening is optiona l if Screening and Day 1 assessments occur on the same day. 
c Collect PK samples on Day 1 in the AM prior to study drug dosing and at 2, 4, 8, and 12 hours (Predose of PM dose); Day 3  
  and Day 5 prior to AM study drug dosing. PK samples to be collected for 8 subjects only.      
d Serum β-hCG for pre-menopausal women. 
e  Telephone follow-up if subject is not in hospital. If subject is  no longer hospitalized or cannot return due to COVID restrict ions,  
a telephone follow-up to record O 2 usage/levels, AEs and conmeds may be con ducted. All other assessments are optional. 
f Subjects may be randomized during the Screening Phase after a ll of the screening assessments are completed and subject is  
   considered eligible for the study or on Day 1.  
g If subject prematurely discontinues from the study or is dischar ged from the hospital on Days 2, 4, or 6 collect biomarker  
   samples in addition to other scheduled assessments. If subj ect prematurely discontinues from the study or is discharged on D ays 1, 3, 5, or 7,  
conduct the study assessments scheduled on those days.  
h The first dose of study drug may be started in the AM or the PM. 
i  Vital signs, ECG and safety labs will be done in intubated subjects only.   
J  Survival status is captured on the NIAID questionnaire. 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 19  of 44 
  
8.0 BACKGROUND 
8.1 Acute Respiratory Di stress Syndrome (ARDS) 
ARDS is recognized as the most severe form of  acute lung injury (ALI), a form of diffuse 
alveolar injury, which is an acute inflammato ry lung process, associated with increased 
pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. The 
acute, intense inflammatory res ponse of the lungs occurs as a result of direct (e.g., toxins, 
infection) or indirect (sepsis, trauma) insult  to the alveolar capillary membrane leading to 
increased permeability and subsequent edema from  vascular leakage resulting in the loss of 
aerated lung tissue ( Ranieri VM et al 2012 , Eworuke et al 2018 ).  ARDS is defined by timing 
(within 1 week of clinical insult or onset of respiratory symptoms ); radiographic changes 
(bilateral opacities not fully explained by effusions, consolidation, or atelectasis); origin of edema (not fully explained by cardiac failure or  fluid overload); and severity based on the 
PaO
2/FiO 2 ratio on 5 cm of continuous positive airw ay pressure (CPAP). The 3 categories are 
mild (PaO 2/FiO 2 200-300), moderate (PaO 2/FiO 2 100-200), and severe (PaO 2/FiO 2 ≤100)  
(Ranieri VM, et al 2012 ).  
8.2 MN-166 (ibudilast) 
MN-166 (ibudilast) is a small molecule macropha ge migration inhibito ry factor (MIF) and 
phosphodiesterase (PDE) 4,10-inhibitor drug candidat e with demonstrated neuroprotective action 
in vitro and in vivo. MIF knockout or anti body-neutralization st udies have provided 
neuroprotection validation in certain multiple sclerosis (MS) and other neurological animal 
models. MN-166 (ibudilast) has a dditionally shown attenuation of g lial cell activation in multiple 
in vitro and in vivo model systems which may represent a novel pharmacotherapeutic approach 
in ALS treatment. 
MN-166 (ibudilast) distributes well to the CN S and is a selective inhibitor of the pro-
inflammatory cytokine, macrophage mi gration inhibitory factor (MIF ( Cho et al 2010 ) and 
certain cyclic nucleotide phosphodiesterases ( Gibson et al 2006 ) at clinically relevant plasma or 
CNS concentrations. MIF inhibi tion or knockout has been link ed to attenuated disease 
progression in animal models of multiple sclerosis ( Powell et al 2005 ; Kithcart et al 2010 ) and 
attenuates neuronal death and promotes re covery in mouse spinal cord injury ( Nishio et al 2009 ). 
Another MIF knockout study revealed its role in neurodegeneration in an experimental stroke 
model ( Inacio et al 2011 ). PDE inhibition has likewise show n some neuroprotective actions (
Chen et al 2007 ; Nakamizo et al 2003 ).  
MN-166 (ibudilast) has been recogn ized to have glial attenuating ac tivity in vitro and in vivo. In 
activated glia cells in vitro, MN-166 (ibudilast) suppresses the production of proinflammatory 
cytokines and increases the production of anti-in flammatory cytokine a nd various neurotrophic 
factors. ( Suzumura et al 1999 ; Kawanokuchi et al 2004 ; Mizuno et al 2004 ). MN-166 (ibudilast) 
also protects hippocampal neurons ( Tominaga et al 1996 ) and oligodendrocytes against 
excitotoxicity ( Yoshioka et al 1998, 2000 ) and astrocytes against apoptosis ( Takuma et al 2001 ). 
In an animal model of cerebral ischemia, ibud ilast reduces white matter lesions and microglial 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 20  of 44 
 activation ( Wakita et al 2003 ). MN-166 (Ibudilast) was also re ported to reduce glial activation 
and attenuate allodynia in several validated anim al models of peripheral and central neuropathic 
pain ( Ledeboer et al 2007 ; Ellis et al 2014 ).   
In addition, MN-166 (ibudilast) suppresses the e xpression of matrix metalloproteinase-9 (MMP-
9) (Lee et al 2012 ; Yagi et al 2010 ). MMP-9 potentially plays an  important role in the 
pathogenesis of ALS and when knocked down in animal models, leads to slower progression of 
the disease ( Kaplan et al 2014 ). 
8.3 Clinical Pharmacology 
The pharmacokinetics of MN-166 has generally b een shown to be dose-proportional both within 
and between studies. Based on prio r trials, steady state plasma C max and AUC 0-24h levels at the 
highest dose (50 mg bid; 100 mg/day) are anticipated to be approximately 116 ng/ml (C max) and 
1613 ng*hr/ml (AUC 0-24h) (study AV411-026 HV group ). All of the trials except for Protocol 
Nos. AV411-009  and AV411-016  have included all concurrent concomitant medications with 
ibudilast dosing at 80 or 100 mg /day. While pharmacokinetic drug- drug interactions have not 
been carefully assessed (or are in progress) , there are no clear pharmacologic or safety 
interactions noted to da te. Please refer to the Investigator’s Brochure  (IB) for tabulated 
summaries and details of the findings.   
8.4 Rationale for Use of Ibudilast for prevention of ARDS 
The rationale for the use of MN-166for preven tion of ARDS is based upon its cellular and 
molecular target actions and recent research in ARDS animal model ( D Yang, Y Yang, Y Zhao,  
2020 ). At the molecular level, ibudilast inhibits  macrophage migration inhibitory factor (MIF) 
and certain cyclic nucleotide phosphodiesterases (PDEs to reduce pro-inflammatory cytokines 
such as IL-1-beta, IL-6, and TNF-alpha ( Cho et al 2010 ; Gibson et al 2006 ). 
8.5 MIF Inhibition and ARDS 
Macrophage migration inhibitory f actor (MIF), a pro-inflammatory cytokine that not only acts on 
macrophages but is also produced by these cells in response to endotoxins , exotoxins, and other 
cytokines such as TNF α and interferon-gamma (IFN- γ) (Bach et al 2009 ).  The critical role of 
MIF in mediating inflammatory lung injury in  ARDS has been discussed. The study identified 
enhanced MIF protein expression in alveolar capillary endothe lium and infiltrating macrophages 
in lung tissues from ARDS patie nts. The possibility that MIF up ‐regulates its synthesis in an 
autocrine fashion in ARDS was tested using cult ured endothelial cells stimulated with MIF and a 
murine model of lipopolysaccharide (LPS)‐ induced acute lung injury. MIF induced significant 
TNFα  synthesis in cultured endothelial cells a nd the effect was blocked by neutralizing anti ‐MIF 
antibody. A similar blocking eff ect was observed when MIF ‐stimulated endothelial cells were 
pretreated with neutralizing anti ‐TNFα  antibody, supporting the noti on that MIF induced TNF α 
production via an amplifying pro ‐inflammatory loop ( Lai et al 2003 ). 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 21  of 44 
 8.6 PDE4 Inhibition and ARDS 
There are multiple studies suggest that potential PDE4 inhibitors for ARDS treatment. In the 
animal model of ALI, roflumilast, PDE4 inhibi tor treatment reduced l eak of cells (P<0.01), 
particularly of neutrophils (P<0.001), into th e lung, decreased lung edema formation (P<0.01), 
and improved respiratory parameters . The results indicate a future potential of PD E4 inhibitors 
also in the therapy of ALI ( Kosutova et al 2017 ). 
The anti-inflammatory effect of two PDE4 inhibito rs was investigated in a pre-term rat model of 
hyperoxia-induced lung injury. Pre-term rat pups were exposed to room air, hyperoxia, or 
hyperoxia and one of two PDE4 inhibitors: rolipram and piclamilast. The anti-inflammatory effects of prolonged PDE4 inhibitor thera py were investigated by studying survival, 
histopathology, fibrin deposition, alveolar vascular leakage, and differential mRNA expression 
(reverse transcription, or RT-PCR)  of key genes involved in infl ammation, alveolar enlargement, 
coagulation and fibrinolysis. PDE4  inhibitor therapy prolonged median survival by up to 7 days 
and reduced alveolar fibrin deposition, lung infl ammation and vascular leakage by decreasing the 
influx of monocytes and macrophages and protei n efflux in bronchoalveolar lavage fluid.   
Analysis of mRNA expression of key genes involved in experimental bronchopulmonary 
dysplasia (BPD) revealed a significant PDE4 i nhibitor-induced improvement of genes involved 
in inflammation, fibrin deposition and alve olarisation. In conclusion, phosphodiesterase-4 
inhibition prolongs survival by inhibiting inflamma tion and reducing alveolar fibrin deposition in 
pre-term rat pups with neona tal hyperoxic lung injury, wher eby piclamilast outperformed 
rolipram (
de Visser et al 2008 ). 
8.7 ARDS animal model study with Ibudilast  
In this study, ibudilast was test ed in a LPS-induced neonatal ARDS animal model to evaluate its 
anti-inflammatory effect. Ibudilast ameliorated LPS-induced pathological manifestations and 
pulmonary edema in lung tissue. In addition, ibud ilast attenuated the secretion of inflammatory 
cytokines TNF-alpha, IL-1 beta, IL-6 and MC P-1 by inactivating the chemokine axis and 
significantly reduced LPS-induced cell apoptosis in lung tissue ( Yang et al 2020 ). 
8.8 Previous Human Experience 
Ibudilast is approved in Japan and South Korea for treatment of  asthma (20 mg/day) and post-
stroke dizziness in cerebrovasc ular disorders (30 mg/day) and has been prescribed for these 
indications for almost 30 years. The largest accu mulation of clinical safety experience with 
ibudilast (MN-166) is fro m the approval of Ketas® for asthma and post-stroke dizziness. Dosing 
was 20 to 30 mg/day (included uses up to 40 mg /day) and based on chronic administration.  In 
the Ketas package insert , the most common adverse events we re anorexia (0.6%), nausea (0.6%), 
increased liver enzymes (ALT 0.4%, AST 0.3%, and GTP 0.4%).  Following regulatory approval, adverse event data continued to be collected a nd, to date, approximately 14,968 
subjects were evaluated. Safety  data was taken from the 2009 Keta s package insert and Interview 
Forms collected from 1989 to 1996. Seven hundred sixty- nine (769) ad verse drug reactions 
occurred in 507 (3.39%) patients. The most common ( ≥5%) adverse drug reactions were: itching 
(8; 0.05%), rash (8;  0.05%), abdominal pain (7 ; 0.05%), heavy head feel ing (7; 0.05%), stomach 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 22  of 44 
 pain (7; 0.05%), epigastric discomfort (8; 0.5% ), BUN increased (7; 0.05%), heart rate/heart 
rhythm disorders (8; 0.05%),ve rtigo (10; 0.7%), serum choles terol increased (10; 0.07%), 
general malaise (10; 0.07%), lack  of appetite (13; 0.09%), head ache (13; 0.09%), heartburn (16; 
0.11%), vomiting (19; 0.13%), nausea (22; 0.15%), stomach discomfort (24; 0.16%), ALP increased (36; 0.24%), AST increased (45; 0.30 %), ALT increased (53; 0.35%), sickness (54; 
0.36%), gamma-GTP increased (54; 0.36%), and anorexia (71; 0.47%). 
9.0 CLINICAL OVERVIEW 
To date, ibudilast has been evaluated in a to tal of 21 ongoing and comple ted clinical trials; 11 
clinical trials by the sponsor a nd 10 trials by investigator and mo re than 750 subjects have been 
exposed.  Eight investigator-ini tiated studies are conducted or ongoi ng in US cross-referenced to 
sponsor’s IND. Two trials were conducted in Australia, one study targeted medication overuse 
headache (Australian CTN File No. 2011/012799) and the other targeted chemotherapy-induced-peripheral neuropathy (Australian CTN File No. 2018/010601).  An overview of the safety profile in each of the Phase 2 clinical trials will be reported below.  
9.1 MediciNova-Sponsored Studies 
Among 10 completed Phase 1 and 2 studies, more  than 620 received ibudilast up 100 mg/d in 
single and multiple doses up to 2 years. 
Ibudilast was tested at dosages of 30 or 60 mg/d up to 2 years in the Phase 2 clinical trial (MN-
166-CL-001) with relapsing-remitting multiple sclerosis (RRMS) patients.  A total of 297 
subjects were randomized; of those, 103 subjec ts were randomized to placebo, 95 subjects were 
randomized to 30 mg/d, and 99 subjects were randomized to 60 mg/d. A total of 291 subjects 
received ibudilast 30 mg/d or 60 mg/d for up to 2 years in the open-label-extension phase. The 
most common treatment related AEs were na usea, headache, and upper respiratory tract 
infection. There were 20 SAEs reported during entir e 2-year duration of the study. All SAEs were 
considered not related to ibudilast in this study. 
In the Phase 2 SPRINT-MS/NN102 trial, a total of  255 progressive MS subjects were enrolled, 129 
subjects received doses of ibudilast up to 100 mg/d and 126 subjects recei ved placebo for up to 96 
weeks. Safety results of study SPRINT-MS/NN102 suggests that the adve rse event profile of 
ibudilast appears to be similar to the pattern of  events seen in the MN -166-CL-001 study at daily 
doses up to 100 mg/day. Most of the adverse events  that appear to be related to ibudilast fall 
under the Gastrointestinal SOC, nausea, vomiting diarrhea, abdominal pain, and dyspepsia. Other 
treatment-related adverse events included fati gue, hepatic enzymes increased, WBC decreased, 
alanine aminotransferase, headache, decrease d appetite, and insomnia. Although there was a 
higher incidence of depression in the ibudilast group, most of the ev ents were considered to be 
unrelated by the principal investigator There were 58 SAEs reported in 44 subjects across both 
treatment groups during the 96 weeks trial. One SAE of ataxia was considered related to 
ibudilast, which was a single event and resolved the next day.  
In the Phase 1b/2a MN-166-ALS-1201 study, 45 subjects with ALS received ibudilast 60 mg/d for up to 52 weeks. Safety results of the MN- 166-ALS-1201 study also show a similar profile to 
the MS studies. The most commonly reported adverse events fall under the Gastrointestinal and 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 23  of 44 
 Nervous System SOCs. The most commonly reported TEAEs in the ibudilast group were dysphagia, nausea, fatigue, pain, upper respiratory in fection, fall, weight loss, anorexia, headache, 
depression, insomnia, cough, and dyspnea. Treatment -related events that were attributed to 
ibudilast were decreased/loss of appetite, a norexia/weight loss, na usea, and ECG changes 
(atrioventricular junctional rhythm), and increa sed QTcB to upper normal of 470 (Brooks et al 
2017).  
In the Phase 2 open-label study (MN-166-ALS-1202) a total of 35 subjects with ALS received 
100 mg/day up to 9 months. The most commonly reported treatment-rela ted adverse event was 
nausea. These studies suggest that ibudilast  at daily doses of up to 100 mg/d  appear to be generally safe 
and well-tolerated. The most commonly reporte d AEs have been nausea, abdominal pain, 
diarrhea, and headaches. There was a slight dose-rel ated increase in the pe rcent of subjects with 
headaches and gastrointestinal AE s. The incidence of nausea s uggested a dose-related increase. 
Ibudilast also appeared to cause  transient changes in laboratory values, particularly AST, ALT 
and GGT which, in most cases, appeared to resolve over time. 
9.2 Study Dose Justification 
In a preclinical model of ARDS in mice, ibudilast 7.5 mg/kg i.p. treatment significantly reduced 
LPS-induced pathological changes and pulmonary  edema in lung tissues. In addition, ibudilast 
treatment attenuated the secretion of inflammatory cytokines IL-1β  beta, IL-6, TNF, and MCP-1, 
and significantly reduced LPS-induced  cell apoptosis in lung tissues.  
Based on internal data, a 7.5 mg/kg dose of ibudila st administered i.p. resulted in an AUC of 
approximately 862 h*ng/mL, an exposure that is achi eved in healthy volunt eers at doses of 30-50 
mg administered twice daily. In ALS patients receiving ibudilast 100 mg pe r day orally, a significan t reduction in MIF was 
observed after treatment. This effect was maintained throughout the 36-week duration of the 
study. 
The safety of a single dose of 100 mg has been established in healthy volunteers. In addition, 
long term safety of up to 96 weeks of 100 mg/day  doses has been established in MS and ALS 
patients without any significant safety sequelae. The 100 mg/day is the dose that is shown to 
exert significant reductions in MIF levels, and ther efore considered the ta rgeted clinical dose. 
9.3 Treatment Duration Justification  
According to CDC, among the COVID-19 patients  who developed severe disease, the medium 
time to dyspnea ranged from 5 to 8 days, the median time to acute respiratory distress syndrome 
(ARDS) ranged from 8 to 12 days, and the me dian time to ICU admission ranged from 10 to 12 
days. According to the published paper discussi ng a total of 191 COVID-19 patients treated in 
Wuhan, China, (Zhou et al 2020 Lancet), the medi an time from illness to dyspnea was 7.0 days, 
median time from illness to onset of ARDS wa s 12 days, and median time from illness to ICU 
admission was 12 days in total patients. The median time from dyspnea to intubation was 10.0 days (IQR 5.0–12.5) for patients who received  invasive mechanical ventilation.  
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 24  of 44 
 The steady-state plasma ibudilast concentrations are reached within 3 da ys of initiating b.i.d. and 
we want to treat at least 5 da ys with steady state drug level, thus, we determined duration of 
treatment to be 7 days. 
10.0 TRIAL OBJECTIVES 
10.1 Primary Objectives 
The primary objectives of the study are to evaluate the: 
• Efficacy of ibudilast vs. placebo in COVI D-19 subjects measured by the proportion of 
subjects free of respiratory fa ilure (i.e., decreased need for O 2 therapy) at Day 28; 
• Efficacy of ibudilast vs. placebo in COVID-19 subjects measured by clinical status (i.e., improvement on NIAID scale) at Day28;  
10.2 Secondary Objectives 
The secondary objectives of the study are to evaluate the: 
• Safety and tolerability of ibudilast  vs. placebo in COVID-19 subjects;  
• Efficacy of ibudilast vs. placebo in COVI D-19 subjects measured by the proportion of 
subjects free of respiratory fa ilure (i.e., decreased need for O
2 therapy) at Days 7, 14, and 
60; 
• Efficacy of ibudilast vs, place bo in COVID-19 subjects by clini cal response of ibudilast 
vs. placebo in COVID-19 subjects  at Days 7, 14, and Day 60;  
• Anti-inflammatory effects of ibudila st vs. placebo on cytokine levels; 
• Pharmacokinetics of ibudilast vs. placebo in COVID-19 subjects. 
11.0 OVERALL STUDY DESIGN 
This is a randomized (1:1), double-blind, placebo- controlled, parallel-group study of ibudilast in 
hospitalized COVID-19 subjects at  risk for developing ARDS receiving standard of care.  The 
study will consist of a Screening Phase followed by a Treatment and Follow-up Phase. Following the Screening Phase, if the subject meets eligibility cr iteria, subject will be randomly 
assigned treatment with MN-166 (ibudilast) or placebo. Upon completion of the 7-day Treatment 
Phase, subject will be follow ed-up at Day 14, Day 28, and Day 60. Subjects will receive ibudilast 
100 mg/d (50 mg b.i.d) or matching placebo ( 50 mg b.i.d.) every day for 7 days.  (See Table 1  
for study assessments). 
11.1 Screening 
The following screening assessments will be performed upon signing the ICF: inclusion/exclusion criter ia review, physical exam , assess vital signs and O
2 use and SpO 2, 
clinical status using the NIAI D scale, 12-lead ECG, draw blood for plasma biomarkers that 
include migration inhibitory factor  (MIF), (interleukin 1-beta (IL-1 β), interleukin 6 (IL-6), tumor 
necrosis factor (TNF- α), C-reactive protein (CRP) and other exploratory biomarkers. A complete 
blood count (CBC), comprehensive metabolic pane l (CMP), D-dimer and coagulation tests will 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 25  of 44 
 also be drawn. A serum pregna ncy test will be done in pre-menopausal females. Prior 
concomitant medications taken within the last 7 days prior to study drug administration will be 
recorded.  
11.2 Treatment Phase 
During the Treatment Phase, hospitalized subjects  will be treated with  MN-166 or placebo for a 
7-day period. During the Treatment Phase, subjects will undergo study-related procedures including physical exam, ECG, O
2 use assessment and SpO 2, biomarkers and PK samples (except 
Day 7) draw, CBC, CMP, D-dimer blood collection, clinical assessment using the NIAID scale, 
and information on adverse events and concomitant  medications will be recorded (see  Table 1 
Schedule of Assessments). 
11.3 Follow-up 
On Study Day 14, if subject is stil l hospitalized, the site will conduct  physical examination, 
clinical status (NIAID  scale), vital signs, O 2 use and SpO 2, CBC, CMP, D-dimer, coagulation 
tests, biomarkers, and AE and c oncomitant medications review.  
On Study Day 28, subject’s clinical status (NIAID scale) and surviv al status will be recorded,  O 2 
therapy status use, AE and conmed review.  A telephone follow-up is permitted if subject is no 
longer hospitalized.  
On Study Day 60, subjects will undergo the following assessments: clinical status using the 
NIAID scale, O 2 therapy status, survival status, AE a nd conmed review. In addition, vital signs, 
12-lead ECG, and clinical safety labs (CBC, CMP, CRP, D-Dimer, PT and INR) will be performed in intubated subjects only.  
11.4 Early Termination/Discharge from Hospital 
If subject early terminates from the study or is  discharged from the hospital on Days 2, 4, or 6, 
the site will conduct clinical assessment, take vital signs, O
2 use and SpO 2, draw biomarker 
sample, and review AEs and concomitant medications .  If subject early terminates from the study 
or is discharged on Days 1, 3, 5, or 7, the si te will conduct the study assessments scheduled on 
those days.  
Subjects who are discharged prior to Day 7 will be given the remainder of their study medication 
to be taken at home and a pulse oximeter supplied by the sponsor to measure their O 2 levels once 
daily until Study Day 14. 
12.0 SELECTION OF SUBJECTS 
12.1 Study Population 
This study will enroll approximately 40 subjects diagnosed with COVID-19 who are at risk for 
developing acute respiratory di stress syndrome (ARDS) receiving standard of care including 
anticoagulation. Randomization of subjects will be  stratified by use of IL-6 antibody therapy.  
 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 26  of 44 
 Subjects who do not meet all of the inclusion crite ria or who meet any of the exclusion criteria 
are not eligible to pa rticipate in the study. 
12.2 Inclusion Criteria 
1. Written or verbal informed consent by subj ect or subject representative is obtained  
2. Male or female subjects age 18 to 80 years, inclusive 
3. SARS-CoV-2 infection confir med with WHO criteria (incl uding a positive PCR of any 
specimen, e.g., blood, respiratory, stool, urine, or any other body fluid) 
4. Chest imaging (radiograph, CT scan or l ung ultrasound) with abnormalities consistent 
with COVID-19 pneumonia 
5. SpO 2 ≤ 92% on room air (RA), RR ≥24 breaths per min on RA, and/or requirement for 
supplemental oxygen  
6. At least 1 risk factor which may put patient at higher risk for more severe illness from 
COVID-19: Age > 65, underlying serious heart dis ease, chronic lung disease, moderate to 
severe asthma, body mass index of ≥ 40 or diabetes 
7. C-reactive protein >35 mg/L 
8. No known allergies to the study drug or its excipients 
12.3 Exclusion Criteria 
1. Suspected active bacterial, fungal, viral, or other cause of respiratory failure other than 
COVID-19 
2. Known or suspected immunosuppression w ith immunosuppressant medications or 
chemotherapeutic agents 
3. Active primary lung cancer or another metastatic malignancy to the lungs 
4. Moderate to severe liver failure (see section 12.4 ) defined by  Child-Pugh score of ≥ 7 
measured by: 
• Total bilirubin 
• Serum albumin 
• INR 
• Ascites 
• Hepatic encephalopathy 
5. The following abnormal laboratory tests if any of the criteria are met: 
a. Platelet Count < 75,000 /mm3 
b. White Blood Count < 2500 /mm3 
c. ALT or AST or Total Bilirubin >3 x ULN 
d. Bilirubin > 3 mg/dL 
e. Serum albumin less than 28 g/L 
6. Subject is on dialysis 
7. On home ventilator support or continuous domiciliary O 2 therapy for baseline lung 
disease  
8. Active tuberculosis (TB) infection 
9. Lactating or pregna nt at Screening  
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 27  of 44 
 10. History of stomach or intestinal surgery or any other condition that co uld interfere with or 
is judged by the Investigator  to interfere with absorpti on, distribution, metabolism, or 
excretion of study drug 
11. Treatment with an investigational drug or o ff-label medication within 5 half-lives or 30 
days whichever is longer pr ior to study drug treatment 
12.  Participating in another COVID-19 clinical trial   
13. Any other serious medical condition or abnorma lity that, in the Investigator’s opinion, 
would preclude partic ipation in the study.  
12.4 Child-Pugh Scoring Table 
Subjects will be excluded from study if  Child-Pugh score at screening is ≥7. 
Table 2 Child-Pugh Scoring Table 
Measure  1 point  2 points  3 points  
Bilirubin (total) mg/dL <2  2-3  >3  
Serum albumin g/L >35  28-35  <28  
INR  <1.7  1.71-2.20  >2.20  
Ascites  None  Mild  Severe  
Hepatic encephalopathy  None  Grade I-II (or 
suppressed with 
medication)  Grade III-IV (or refractory)  
12.5 Screen Failures 
A Screen failure is defined as a potential subject who did not meet  one or more criteria required 
for participation who consent to participate in the clinical trial but is not subsequently randomly 
assigned to the study interventi on or entered in the study.  
Individuals who do not meet the cr iteria for participation in this trial (screen failure) due to 
abnormal clinical laboratory results  may be rescreened. Study sta ff should notify sponsor prior to 
rescreening. 
12.6 Subject Withdrawal/Discontinuation Criteria 
A subject may request to be withdrawn fr om the study at any time for any reason.  
The Investigator may interrupt the treatment of any subject whos e health or well-being may be 
compromised by continuing participation in the study. The following instances require subjects 
to be withdrawn from the study: 
• Subject fails to adequately comply with th e dosing, evaluations, or other requirements of 
the study at the discre tion of Investigator 
• Subjects who have adverse events that require discontinuation of study medication 
• Subjects who, in the opinion of the Investig ator, should be discontinued for their well-
being  
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 28  of 44 
 • Subjects who are no longer able to understa nd task instructions or to perform tests 
adequately 
• Subject becomes pregna nt during the study. See Section 18  for reporting requirements 
and follow-up of the pregnancy 
If a subject withdraws or is removed from th e study for any reason, the reason and date of 
discontinuation of study medication should be record ed in the appropriate section of the Case 
Report Form (CRF). At the time of study disconti nuation, every effort should be made to ensure 
that the scheduled study procedur es and evaluations for that da y are performed. Subjects who are 
discontinued from study drug for reasons other than loss to follow- up or withdrawal of consent 
will remain in the study and continue regularly  scheduled efficacy and safety assessments.  
The study sponsor reserves the right to discont inue the study at any time for medical or 
administrative reasons.   
12.7 Subject Stopping Criteria 
A subject should be withdrawn from the study if any of the following abnormal lab values occur, 
after repeat testing:  
• AST or ALT or total bilirubin >3 x upper limit of normal (ULN) 
• Bilirubin >3 mg/dL 
• Serum albumin less than 28 g/L 
• White blood count <2500/mm3 
• Platelet count <75,000/ mm3 
A subject should also be withdraw n from the study if any of the fo llowing adverse events occur: 
• Nausea considered moderate or severe and related to study drug by investigator for 
greater than 3 consecutive days despite maximal supportive therapy 
• Vomiting considered moderate or severe a nd related to study drug by investigator for 
greater than 3 consecutive days despite maximal supportive therapy 
• Diarrhea considered moderate or severe and related to study drug by investigator for 
greater than 3 consecutive days despite maximal supportive therapy 
• Occurrence of an SAE or  grade 3 adverse event related to study drug 
Subjects who are withdrawn/disc ontinued from study drug to an abnormal lab result or adverse 
event will remain in the study and continue regul arly scheduled efficacy and safety assessments. 
 
12.8 Study Stopping Criteria  
An independent medical safety monitor will ev aluate safety on an ongoing basis during the 
study. After each of the first thr ee subjects are dosed, the medical safety monitor will review the 
data with the PI and sponsor and will make a recommendation to proc eed/stop. After the first 
three subjects are evaluated, the medical safety monitor will continue to review safety data 
throughout the study.  
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 29  of 44 
 If two or more subjects experi ence similar adverse events of m oderate or severe intensity or 
similar serious adverse events related to study dr ug or if two or more subjects discontinue study 
treatment due to safety concerns, study dosing will be temporarily halted until the safety data has been reviewed. Once reviewed by an indepe ndent safety monitor, sponsor and PI, a 
determination will be made to continue or stop the study.  
13.0 TREATMENTS 
MN-166 (ibudilast) will be administered as MN -166 50 mg (5 capsules) b.i.d for 7 days. Study 
drug may be taken with food or within an hour of eating to improve gastroin testinal tolerability. 
Subjects who cannot tolerate a b.i.d. dosing regime n may be administered a t.i.d. dosing regimen 
(40 mg at breakfast, 30 mg at lunch, 30 mg dinner). Subjects who cannot tolerate this regimen will be discontinued from the study.   
Day 1 study drug may be administered starting with the PM dose. If the first dose of study drug is 
administered in the PM then the last dose should be administered on Study Day 8 in the AM.  
Matching placebo will also be provided and will be  administered as 50 mg (5 capsules) b.i.d. for 
7 days. 
13.1 Study Drug Supply 
MN-166 and matching placebo will be provided in 10 mg non-vegetarian capsules in 
polyethylene bottles and will be stored at room temperature.  
MN-166 is an extended release pharmaceutical preparation comprised of white extended release 
granules contained in a No.4 white capsule ( Table 3 ).  
 Table 3 Study Drug Information 
Investigational Drug MN-166 or matching placebo 
Formulation 10 mg capsules 
Frequency MN-166: 50 mg b.i.d. for 7 days  
Storage Conditions Store at room temperature  
13.2 Study Drug Packaging and Labeling 
At a minimum, the following information will be included on each package:  
• Name of Sponsor  
• Study number/Acronym/IND number 
• Route of administration 
• Quantity of dosage unit 
• Directions for use 
• Storage conditions 
• Space for information to be completed by Investigator/designee: 
o Name and telephone number of Investigator 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 30  of 44 
 o Dispensing date 
o Subject number 
• Statement “Caution: New Drug – Limited by federal law to investigational use” 
13.3 Study Drug Storage 
The study drug should be stored at room  temperature. Do not freeze.    
13.4 Study Drug Administration 
 The study drug will be dispensed by appropriately qualified site study staff.  
Investigational clinical  supplies will be received by the PI  or a designated person at the study 
site, handled and stored safely and properly, and kept in a secured location to which only the 
Investigator and/or designated as sistants have access. Clinical supplies are to be dispensed only 
in accordance with the protocol.  
Study drug will be administrated orally. If subj ects become dependent on a gastric tube, study 
drug can be given via gastric tube  by opening the capsules in an en teral syringe, then suspend in 
30 ml distilled water. It is r ecommended that the gastric tube is rinsed before and after each 
study drug delivery via gastric tu be. Study drug is extended-releas e granule in gelatin capsule 
and gelatin capsule has no functi onality in the release of drug.  
Also, open capsule MN-166 administration has been used in 2 clinical trials in ALS patients 
who became gastric tube dependent due to bulbar symptoms, with no safety concerns. 
13.5 Dose Interruptions 
The following abnormal laboratory test s should be repeated within 24 hours if any of the criteria 
are met: 
• AST or ALT or Total Bilirubin >3 x upper limit of normal (ULN) 
• Bilirubin >3 mg/dL 
• Serum albumin less than 28 g/L 
• White blood count <2500/mm3 
• Platelet count <75,000/ mm3 
If, after repeat testing, the labor atory value is still outside the above-stated limits, then the subject 
should stop study medication. While dosing is wit hheld, subjects will continue tests and 
assessments according to the schedule defined in  the protocol (and may also undergo additional 
assessments to evaluate the laboratory abnormality as  per the Investigator’s standard practice).   
13.6 Method of Assigning Subjects to Treatment Groups 
Subjects will be assigned to treatments base d on a randomization scheme generated by a 
computer program. The randomization scheme will be reviewed and approved by an independent 
statistician from the Sponsor and locked after approval. 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 31  of 44 
 13.7 Blinding 
The subject and all study staff members including the Sponsor will be blinded to the treatment 
codes. Randomization information will be kept strictly confidential, filed securely by an 
appropriate group at the sponsor  company and accessible only to  authorized personnel until the 
time of unblinding. 
13.8 Prohibited Medication 
The use of any unauthorized investigationa l therapy is prohibited during the study.  
13.9 Treatment Compliance 
Records of treatment compliance for each subjec t will be kept throughout the study. The clinical 
research monitor will review trea tment compliance during site visits and at the completion of the 
study. 
14.0 STUDY PROCEDURES 
14.1 Informed Consent 
The Principal Investigator or a qualified designee (e.g., a license d, qualified medical practitioner 
such as a physician’s assistant or a nurse pr actitioner) listed on FDA Form 1572 will explain the 
study to the subject or subject’s representative, answer all of th e subject’s questions, and obtain 
written or verbal informed consent before performing any study-related procedure. Informed 
Consent should be conducted in accordance with local requirements. Subject should be able to 
verbally describe the benefits and risks associ ated with this study and what other treatment 
alternatives are availabl e (as described in the Informed Consent form).  
Only subject or subject’s representative who provide informed consent, as assessed and 
documented by the Investigator, will be enrolled . The subject is requir ed to provide written 
informed consent prior to undergoing any study pro cedures. If subject is una ble to sign their full 
name, an “X” can be acceptable. A copy of the signed and dated informed consent (in a language 
in which the subject is fluent) is required to be given to the subject. If a subject withdraws 
consent, data collected up to the time of discon tinuation will be used to evaluate study results. 
14.2 Clinical Lab Testing 
Clinical laboratory testing (CMP, CBC, and coa gulation) will be performed at Screening, Day 
1, Day 3, Day 5, Day 7, Day 14 and Day 60 (in int ubated subjects only) at the site’s local 
laboratory.  
 Table 4 CMP, CBC, and Coagulation Tests 
Comprehensive Metabolic Panel (CMP) Complete Blood Count (CBC) with Diff  
Serum albumin white blood cell count (WBC) 
blood urea nitrogen (BUN) white blood cell differential 
calcium eosinophilic leukocyte count 
carbon dioxide (bicarbonate) basophilic leukocyte count 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 32  of 44 
 chloride neutrophil count 
Serum creatinine lymphocyte count 
glucose monocyte count 
potassium platelet count 
sodium red blood cell count (RBC) 
total bilirubin hemoglobin 
total protein hematocrit 
alanine aminotransferase (ALT) D-dimer 
alkaline phosphatase (ALP)        PT 
aspartate aminotransferase (AST)        INR 
GFR (estimated- will be autocalc by 
database)  
 
14.3 Biomarker Samples 
The biomarker samples, migration inhibitory  factor (MIF), (int erleukin 1-beta (IL-1 β), 
interleukin 6 (IL-6), tumor necrosis factor (TNF α), C-reactive protein (CRP), and other 
exploratory markers will be sent to a central laboratory. Biomarker samples will be collected at 
Screening, Day 1, Day 3, Day 5, Day 7, and Da y 14. See Laboratory Manual for biomarker 
sample collection, processing, and shipping. 
14.4 Pharmacokinetic (PK) Samples 
Pharmacokinetic samples will be collected on Day 1: AM Predose, and at 2, 4, 8 and  
12 hours (Predose of PM dose), and on Day 3 and Day 5 at AM Predose.  
 
PK samples will be collected for 8 subjects only.  
See Laboratory Manual for PK co llection, processing, and shipping. 
14.5 Clinical Assessment Scale 
At Screening and on Study Days 1 through 7, and on Days 14 28, and Day 60 of the Follow-up 
visits, subjects will be assessed using the NIAID 8-point ordinal scale: 
1) Death;  
2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane 
oxygenation (ECMO);  3) Hospitalized, on non-invasive ventilation or high flow oxygen devices;  4) Hospitalized, requirin g supplemental oxygen;  
5) Hospitalized, not requiring suppleme ntal oxygen - requiring ongoing medical care 
(COVID-19 related or otherwise);  6) Hospitalized, not requiring supplemental  oxygen - no longer requires ongoing medical 
care;  7) Not hospitalized, limitation on activ ities and/or requiring home oxygen;  
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 33  of 44 
 8) Not hospitalized, no limitations on activities  
15.0 STUDY ASSESSMENTS 
15.1 Screening 
After signing of informed consent form the following assessments will be performed: 
• Inclusion/Exclusion criteria review 
• Conduct brief physical exam 
• Assess clinical status using NIAID scale 
• Assess vital signs (BP, RR, HR, Temp) 
• Conduct ECG 
• Assess O 2 use including CPAP, BiPAP, and nasal cannula and SpO 2 
• Collect blood sample for biomarkers *(MIF, IL-1 β, IL-6, TNF- α) 
• Complete blood count (CBC), comprehensive metabolic panel (CMP), CRP, D-dimer, 
and coagulation test (PT and INR) 
• Collect serum β-hCG in pre-menopausal women 
• Record prior medication use within the past  7 days prior to study drug administration 
 
*Biomarker blood sample collection is optiona l at Screening if the Screening and Day 1 
assessments occur on the same day but the samp le must be collected pre-study drug dosing. 
15.2 Randomization 
Once all of the screening assessments have been conducted, subject will be randomized. Randomization will be stratified according to su bject’s use of IL-6 antibody therapy and may 
occur on either the last day of screening or the morning of Day 1. 
15.3Treatment Phase  
       15.3.1 Day 1 (Baseline), Day 3, Day 5 and Day 7 
• Brief physical exam 
• Assess clinical status using NIAID scale 
• Assess vital signs (BP, RR, HR, Temp),  
• Assess O
2 use including invasive mechanical ventilation, non-invasive ventilation 
(CPAP, BiPAP, nasal cannula high-flow oxygen), or ECMO and SpO 2  
• 12-lead ECG (check between 2-4 hours after AM dose of study drug)  
• Collect blood sample for biomarkers (MIF, IL-1 β, IL-6, TNF α) 
• Collect PK samples (except Day 7)  
• Comprehensive Metabolic Panel (CMP), Co mplete Blood Count (CBC), CRP, D-dimer, 
PT, INR 
• Adverse events review 
• Concomitant medication review  
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 34  of 44 
 • Administer study drug (Study drug is administered every day on Days 1 through 7) 
 
15.3.2 Day 2, Day 4, and Day 6 
• Assess clinical status using the NIAID scale 
• Assess vital signs (BP, RR, HR, Temp) 
• Assess O 2 use including invasive mechanical ventilation, non-invasive ventilation 
(CPAP, BiPAP, nasal cannula high-flow oxygen), or ECMO and SpO 2 
• Administer study drug  
• Adverse events review 
• Concomitant medication review  
 
15.3.3 Follow-up Phase (Day 14 Day 28 and Day 60) 
The Follow-up Phase consists of a Day 14, Day 28, and Day 60 visit.  
Day 14  
• Brief physical exam 
• Assess clinical status using NIAID scale 
• Assess vital signs (BP, RR, HR, Temp) 
• Assess O
2 use including invasive mechanical ventilation, non-invasive ventilation 
(CPAP, BiPAP, nasal cannula high-flow oxygen), or ECMO and SpO 2 
• Collect blood sample for biomarkers (MIF, IL-1 β, IL-6, TNF α)  
• Comprehensive Metabolic Panel (CMP), Co mplete Blood Count (CBC), CRP, D-dimer, 
PT, INR 
• Adverse events review 
• Concomitant medication review  
 
If subject is no longer hosp italized or cannot return due to COVID restrictions,  
a telephone follow-up to record O 2 usage/levels, AEs and conmed s may be conducted. All other 
assessments are optional.  
Day 28  
 
• Assess clinical status using NIAID scale 
•  Assess O
2 use including invasive mechanical ventilation, non-invasive ventilation 
(CPAP, BiPAP, nasal cannula high-flow oxygen), or ECMO and SpO 2 
• Survival status 
• Adverse events review 
• Concomitant medication review  
 If subject is not in th e hospital, a telephone fo llow-up may be conducted. 
 
 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 35  of 44 
 Day 60   
The following assessments will be performed in all subjects: 
• Assess clinical status using NIAID scale 
• Assess O
2 use including invasive mechanical vent ilation, non-invasive ventilation (CPAP, 
BiPAP, nasal cannula high-flow oxygen), or ECMO and SpO 2 
• Survival status 
• Adverse events review 
• Concomitant medication review  
 
In addition, for subjects who are intubated (at screening or during the study) perform the 
following: 
• Vital signs (BP, RR, HR, Temp)  
• 12-lead ECG  
• Comprehensive Metabolic Panel (CMP), Co mplete Blood Count (CBC), CRP, D-dimer, 
PT, INR  
 
 
 
15.3.4 Early Termination/Discharged from Hospital 
If subject is no longer hospitaliz ed or cannot return due to COVID restrictions, a telephone 
follow-up to record O 2 usage, AEs and conmeds taken will be conducted. All other assessments 
are optional. 
 If subject terminates early from the study or is discharged from the hospital prior to completion 
of the Treatment Phase, complete assessments scheduled for that Study Day. If subject discontinues or are discharged on Days 2, 4, or 6, collect a biomarker sample in addition to their regularly scheduled assessments.    Subjects who are discharged prior to Day 7, will be given their study medication to be taken at 
home and a pulse oximeter (ClinicalGuard CMS-50DL Fingertip Pulse Oximeter) supplied by the sponsor to record their O
2 saturation once daily until Day 14.  
  
16.0 SAFETY ASSESSMENTS  
Adverse events (serious and non-serious) includi ng all Suspected Unexpected Serious Adverse 
Reactions (SUSARs) should be collected from time of first dose of study drug until the end of 
their participation in the study (i.e., the subjec t has discontinued or co mpleted the follow-up 
visit). 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 36  of 44 
 The PI or a qualified designee listed on Form FDA 1572 must asse ss the severity and 
relationship to study medi cation for all AEs.  
The PI, sub-investigator (Sub-I) a nd members of the clinical rese arch team are responsible for 
identifying adverse events and reporti ng them to the RN/study coordinator. 
For all AEs, the Investigator must pursue and obtain information adequate to determine the 
outcome of the AE and to assess whether it m eets the criteria for classification as an SAE 
requiring immediate notification to the Spons or or its designated representative.  
For all AEs, sufficient information should be obtained by the Investigator to determine the 
causality of the AE. The Investig ator is required to assess causality and indicate that assessment 
on the CRF. For treatment-emergent AEs with a causal relationship to the investigational 
product, follow-up by the Investigator is requi red until the event or its sequelae resolve or 
stabilize at a level acceptable to the Investigator, and Sponsor c oncurs with that assessment.  
16.1 Definition of Adverse Event 
An adverse event (AE) is any untoward medical occurrence in a study subject administered an 
investigational medicinal product and which does not necessarily ha ve a causal relationship with 
this treatment. An AE can therefore be a ny unfavorable and unint ended sign (including a 
clinically significant abnormal la boratory finding), symptom, or disease temporally associated 
with the use of the investigati onal medicinal product, whether or not considered related to the 
investigational medicinal product.  Adverse events may include the onset of a new illness and the 
exacerbation of pre-existing conditions. 
16.2 Assessment of Adverse Events 
The PI or will assess all AEs for severity, re lationship with study medication, and whether it 
meets the criteria for classification as a SAE, requiring immediate notificat ion to the Sponsor or 
designee. These assessments will be made in accordance with the standard ratings detailed in the following sections. 
16.3 Severity Assessment 
The severity of AEs will be determined as described in 
Table 5 . 
Table 5 Adverse Events Severity Definitions 
Mild 
Grade 1 Ordinarily transient symptoms that do not influence performance of subject’s 
daily activities.  
Moderate Grade 2 Marked symptoms sufficient to make the subject uncomfortable. Moderate 
influence on performance of subject’s daily activities.  
Severe 
Grade 3 Symptoms cause considerable discomfort. Substantial influence on subject’s daily 
activities.  
Life-threatening Grade 4 Extreme limitation in activity, significant assistance required; significant 
medical/therapy intervention required hospitalization probable. 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 37  of 44 
 When changes in the severity of an AE occu r more frequently than once a day, the maximum 
severity for the event should be noted for that  day. Any change in severity of signs and 
symptoms over a number of days will be cap tured by recording a new AE, with the amended 
severity grade and the date (and time, if known) of the change. 
16.4 Relationship to Study Drug 
One of the following categories in Table 6  should be selected based on medical judgment, 
considering the definitions belo w and all contributing factors. 
Table 6 Adverse Events Causality Definitions 
Related 
 A clinical event, including laboratory test abnormality, occurs in a plausible time 
relationship to treatment administratio n, and which cannot be explained by 
concurrent disease or other medications or chemicals.  
Probably related 
 A clinical event, including laboratory test abnormality, occurs within a 
reasonable time sequence to administration of the treatment, unlikely to be attributed to concurrent disease or other medications or chemicals, and which follows a clinically reasonable response on withdrawal.  
Possibly related 
 A clinical event, including laboratory test abnormality, occurs within a 
reasonable time sequence to administration of the treatment, but which could also be explained by concurrent disease or other medications or chemicals. 
Information on treatment withdrawal may be lacking or unclear. 
Unlikely related 
 A clinical event, including laboratory test abnormality, occurs with a temporal 
relationship to treatment administration that makes a causal relationship 
improbable, and in which other medications, chemicals, or underlying disease 
provide plausible explanations. 
Unrelated 
 A clinical event, including laboratory test abnormality, occurs with little or no 
temporal relationship with treatment administration. Typically explained by extraneous factors (e.g., concomitant di sease, environmental factors, or other 
medications or chemicals). 
16.5 Recording Adverse Events 
Adverse events should be collected and recorded  for each subject from the date the patient 
receives study drug until the end of their pa rticipation in the study, (i.e., the subject has 
discontinued or completed the st udy) through the follow-up visit.  
Adverse events may be volunteered spontaneously by the study subject, or discovered by the 
study staff during physical examinations or by asking an open, non-leadi ng question such as, 
“How have you been feeling since you were la st asked?” All AEs and any required remedial 
action will be recorded in the subject’s s ource documentation and transcribed onto the 
appropriate CRF page for the st udy period indicated. The nature of  AE, date (and time, if known) 
of AE onset, date (and time, if known) of AE outcome to date, severity, and action taken of the 
AE will be documented together with the PI’s or an authorized physician’s assessment of the 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 38  of 44 
 seriousness of the AE and causal relationship to  study medication and/or study procedure (at the 
time of assessment). 
All AEs should be recorded individually in th e study subject’s own words (verbatim) unless, in 
the opinion of the PI or an authorized physicia n, the AEs constitute components of a recognized 
condition, disease, or syndrome. In the latter cas e, the condition, disease, or syndrome should be 
named rather than each individual symptom. The AEs will subsequently be coded using the most 
current version of MedDRA. 
16.6 Treatment and Follow-Up of Adverse events (AEs) 
Appropriate measures should be taken to treat AEs as necessary, and the response of the study 
subject should be monitored and recorded. Clinical, laboratory, and diagnostic measures should 
be obtained as needed, and the results of which should be recorded in the subject’s source 
documentation and transcribed onto the appropriate CRF page. 
All SAEs will be followed until re solution, stabilization of the condition, the event is otherwise 
explained, or the subject is lost to follow-up. 
16.7 Serious Adverse Events (SAEs) 
An AE is considered serious if it meets one or more of the following criteria: 
• Results in death 
• Is life-threatening (i.e., a subjec t is at immediate risk of d eath at the time of the event, 
not an event where occurrence in a more severe form might have caused death) 
• Requires inpatient hospitalization or prolongation of exis ting hospitalization 
• Results in persistent or significant disability/incapacity 
• Results in a congenital anomaly/birth defect 
• Is another important medical event (see below) 
Important medical events that do not result in death, are not life-threat ening, or do not require 
hospitalization may be considered SAEs when, based on appropriate medical judgment, they 
may jeopardize the subject and may require medical or surgical inte rvention to prevent one of the 
outcomes listed above. Examples of such medi cal events include allergic bronchospasm 
requiring intensive treatment in an emergency ro om or in a physician’s office, blood dyscrasias 
or seizures that do not resu lt in inpatient hospitalization, and the development of drug 
dependency or drug abuse. A distinction should be drawn between serious and severe AEs. 
Severity is a measure of intensity whereas se riousness is defined by the criteria above. For 
example, a mild degree of gastrointestinal bl eeding requiring an overnight hospitalization for 
monitoring purposes would be considered an SAE but  is not necessarily severe. Similarly, an AE 
that is severe in intensity is not necessarily an SAE. For example, alopecia may be assessed as 
severe in intensity, but would proba bly not be considered an SAE. 
16.8 SAE Reporting Requirements 
The PI or an authorized delega te is responsible for faxing the requested SAE information to the 
Sponsor or designee within 24 hours or as soon as  possible after learning of the event. Following 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 39  of 44 
 the end of the subject’s participa tion in the study, the PI or an au thorized delegate should report 
SAEs “spontaneously” if considered at least possibly related to study medication. 
Notification of the SAE must be se nt by fax (+01 858-404-0048) or email 
(safetyreports@medicinova.com) in the form of  a completed SAE Report to the Sponsor. As a 
minimum requirement, the initial notification should provide the following information: 
• Study number 
• Subject number 
• Gender 
• Date of birth 
• PI’s name and full study site address 
• Details of SAE 
• Criterion/criteria for clas sification as “serious” 
• Study medication name, or code if blinded, and treatment start date 
• Date of SAE onset 
• Causality assessment  
Initial reports of SAEs must be followed later with detaile d descriptions, including clear 
photocopies of other documents as necessary (e. g., hospital reports, consultant reports, autopsy 
reports, etc.), with the study subject’s personal identifiers removed. All relevant information 
obtained by the PI or an authorized delegate th rough review of these docum ents will be recorded 
on the AE eCRF page and/or a new SAE Report Form and faxed to the Sponsor  or designee  
within 24 hours of receip t of the information. If a new SAE Report Form is faxed, the PI must 
sign and date the form. The Sponsor  may also request additional in formation on the SAE, which 
the PI or an authorized delegate must fa x to the Sponsor (+01 858-404-0048) or designee  within 
24 hours of the request using a new SAE Report Form, bearing the PI’s signature and date. 
Any AE fulfilling the criteria for expedite d reporting will be reported by the Sponsor to 
regulatory authorities and Investigators and I RB/IEC(s) in accordance with the Sponsor’s 
standard operating procedures (SOP ) and local regulatory requirements. 
The PI should report all Investigational New Drug Application safety alerts received from the 
Sponsor to the local or central IRB. 
  17.0 GUIDANCE FOR OVERDOSE  
There is no clinical experience  with MN-166 overdose in huma ns and there is no available 
specific antidote (i.e., rescue pr otocol) to the effects of MN-166. Standard symptomatic support 
measures should be used in the case of ex cessive pharmacological effects or overdose. 
18.0 REPORTING AND FOLLOW-UP OF PREGNANCIES 
If any study subject or subject’s partner becomes pregnant after receiving the first dose of study 
medication and until the follow-up period specified in the protocol, the PI or an authorized 
delegate should submit a Pregnancy Report Form to  the sponsor within 24 hours of the PI or an 
authorized delegate first becomi ng aware of the pregnancy. If a pr egnancy is to be terminated, 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 40  of 44 
 the anticipated date of termination sh ould also be provided in the “Additional 
Information/Comments” field of the Pregnancy Report Form. If a maternal SAE is reported for 
the study subject during th e initial notifica tion of pregnancy, a separate SAE Report Form should 
also be completed and submitted to the sponsor within 24 hours of the PI or an authorized 
delegate first becoming aware of the SAE.  
Subjects who become pregnant while in the stud y should be followed for the duration of their 
pregnancy. If the pregnancy is discovered betw een regularly scheduled study visits, subjects 
should return for an unscheduled visit to return their study medication. A quantitative β-hCG 
should be obtained and subjects s hould be encouraged to return for follow-up visits. If follow-up 
visits are not possible, the PI should collect information about the pregnancy such as 
spontaneous or elective termination, details of birth, and presence or absence of birth defects, congenital abnormalities, or maternal and newborn complications. 
The Sponsor will request that the PI follow the progress of the study subject’s pregnancy with 
the doctor medically responsible  for the pregnancy. A new Pregnancy Report Form should be 
submitted within 24 hours of the PI or an authorized delegate first becoming aware of any new 
information. 
If additional information on the outcome of the pregnancy and/or the details of the birth/delivery 
is received “spontaneously” by the study site, the PI  or authorized delegate should also submit a 
Pregnancy Report Form within 24 hours of becoming aware of the information. If the outcome of 
the pregnancy is reported as premature birth, or  as elective termination due to a medical reason 
or as spontaneous or accidental miscarriage, the details of the outcome should be described in the 
“Additional Information/Comments” field of the Pregnancy Report Form. The pregnancy 
outcome will generally be reported as a follow-up report.  
An SAE Report Form should be co mpleted if the delivery outcome meets the criteria for a SAE 
(e.g., congenital anomaly/birth defect, stillbirth, some other sickness, etc.). The SAE Report 
Form should be completed with the study subject’s details (e.g., subject numb er, initials, date of 
birth, investigational product in formation, etc.) and the details of the fetal SAE and maternal 
complications should be described in the “Narrative” field of the SAE Report Form. 
If a pregnancy is reported for th e study subject’s partne r, the sponsor will provide instructions on 
how to collect pregnancy information in accordance with local requirements. 
19.0 STATISTICAL CONSIDERATIONS 
Full details of the statistical methods including handling of mi ssing data and deaths will be 
outlined in the statistical analysis plan. Since th is is an early proof of concept study, no formal 
sample size calculations have been performed.  
19.1 Analysis Population 
Full Analysis Set: All subjects who sign informed consen t, are randomized, receive treatment 
and have at least one post dose efficacy assessment. 
Per Protocol Analysis: all randomized subjects who suffici ently complied with the protocol. 
Details of the evaluability criteria will be  outlined in the statistical analysis plan. 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 41  of 44 
 19.2 Primary Endpoints 
• Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirements (invasive mechanical ventilation, non-invasive ventilation, high-
flow oxygen, or ECMO, CPAP, BiPA P, nasal cannula) at Day 28 
• Incidence of mechanical vent ilation /intubation at Day 28  
• Mean change from baseline in clinical stat us using the NIAID 8-poi nt ordinal scale at 
Day 28 
• Percentage of patients with at  least a one-point improvement in clinical status using the 
NIAID 8-point ordina l scale at Day 28 
• All cause mortality at Day 28  
19.3 Secondary Endpoints 
• Incidence, frequency, and severity of advers e events at Day 7, 14, 28, and Day 60 Mean 
change from baseline of the following para meters at Day 7, 14, and Day 60 (in intubated 
subjects only): 
o Mean change from baseline in ALT 
o Mean change from baseline in AST 
o Mean change from baseline in serum creatinine 
o Mean change from baseline in BUN 
o Mean change from baseline in complete blood count 
o Mean change from baseline total bilirubin 
o Mean change from baseline in D-dimer 
• Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirement (invasive mechanical vent ilation, non-invasive ventilation, high-flow 
oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Days 7, 14, and Day 60 
• Incidence of mechanical ventilation /intubation at Day 7, Day 14, and Day 60 
• Incidence of ICU admission 
• Mean change from baseline in clinical stat us using the NIAID 8-poi nt ordinal scale at 
Days 7, 14, and Day 60   
• Percentage of patients with at  least a one-point improvement in clinical status using the 
NIAID 8-point ordinal scale at Day 7, Day 14, and Day 60  
• All-cause mortality at Days 7, 14, and Day 60  
• Mean change from baseline in migration inhi bitory factor (MIF), interleukin 1-beta (IL-
1β), interleukin 6 (IL-6), tu mor necrosis factor (TNF α), and C-reactive protein (CRP) at 
Day 7 
• PK plasma concentrations  
19.4 Safety Analysis 
The incidence of treatment-emergent AEs (TEAEs, defined as AEs occurring from the time of first dose through 7 days after the last dose of  study medication), SAEs and AEs leading to 
discontinuations will be summarized by treatm ent group. Incidence of TEAEs will also be 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 42  of 44 
 summarized by severity (mild, moderate, or severe), as well as by relationship to treatment (not related, possibly related, or proba bly related) and by seriousness. 
19.5 Pharmacokinetic Analysis 
Plasma concentrations of MN-166 will be summarized.  
20.0 ETHICS 
20.1 Ethics Review 
Documented approval from the IRB will be obtained for all participating centers prior to clinical 
trial start, according to ICH (International Conference on Harmonization) GCP, local laws, 
regulations, and organization. When necessary, an  extension, amendment or renewal of the IRB 
approval must be obtained. 
20.2 Ethical Conduct of the Study 
The procedures set out in this c linical trial protocol pertaining  to the conduct, evaluation, and 
documentation of this clinical trial, are desi gned to ensure that the Sponsor and Principal 
Investigator abide by Good Clinical Practice Guidelines (GCP). The clinical trial will also be 
carried out in accordance with applicab le local law(s) and regulation(s).  
20.3 Written Informed Consent 
An information and consent form will be provided to the subject. The process of obtaining 
informed consent must be in accordance with applicable regulatory requirements and must 
adhere to GCP and ethical principles in the Declaration of Helsinki. Written informed consent 
must be obtained and documented before any clin ical trial-specific pr ocedure takes place. 
Participation in the clinical trial and date of  informed consent given by the subject must be 
documented in the subject files. 
20.4 Confidentiality 
By signing this protocol, the Inves tigator affirms to the Sponsor that information furnished to the 
Investigator by the Sponsor will be maintained in confidence and such information will be divulged to the IRB or similar or expert comm ittee; affiliated institution; and employees only 
under an appropriate understanding of confidentia lity with such board or committee, affiliated 
institution, and employees.   
 
 
  
 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 43  of 44 
 21.0 REFERENCES 
Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M. The role of macrophage  
inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009;115(10):2031 –
2040. doi:10.1002/cncr.24245  
Chen RW, Williams AJ, Liao Z, Yao C, Tortella FC , Dave JR. Broad spectrum neuroprotection profile of  
phosphodiesterase inhibitors as related to modul ation of cell-cycle elements and caspase-3  
activation. Neurosci Lett 2007(418):165-9 . 
Cho, Y, Crichlow GV, Vermeire JJ, et al. Allosteric  inhibition of macrophage migration inhibitory factor  
revealed by ibudilast. PNAS – USA, 2010 Jun 22;107(25):11313-8 . 
De Visser YP, Walther FJ, Laghmani EH, van Winjngaarden S, Nieuwland K, Wagenaar GT.  
Phosphodiesterase-4 inhibition attenuates pulmona ry inflammation in neonatal lung injury. Eur  
Respir J 2008 Mar;31(3):633-44. Epub 2007 Dec 19 . 
Ellis A, Wieseler J, Favret J, Johnson KW, Rice KC, Maier SF, Falci S, Watkins LR. Systemic  
administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia  
in a novel rat model of central neuropathic  pain. J Pain. 2014 Apr;15(4):407-21. doi:  
10.1016/j.jpain.2013.12.007. Epub 2014 Jan 9. PMID: 24412802; PMCID: PMC3972272 . 
Eworuke E, Major JM, Gilbert McClain LI. Nationa l incidence rates for Acute Respiratory Distress  
Syndrome (ARDS) and ARDS cause-specific factor s in the United States (2006-2014). J Crit Care.  
2018 October; 47:192-197. doi: 10.1016/j.jcrc.2018.07.002 Epub 2018 Jul 10.  
Gibson L, Hastings S, McPhee I, Clayton R, Darro ch C, Mackenzie A, Mackenzie F, Nagasawa M,  
Stevens P, Mackenzie S. The inhibitory profile of ibudilast against the human phosphodiesterase  
enzyme family. Eur J Pharmacol 2006 24;538(1-3):39-42 . 
Inacio AR, Ruscher K, Leng L, et al. Macrophage migration inhibitory factor promotes cell death and  
aggravates neurologic deficits after experime ntal stroke. J Cereb Blood Flow Metab 2011  
Apr;31(4):1096-106. Epub 2010 Nov 10 . 
Kaplan A, Spiller KJ, Towne C, et al. Neuronal matr ix metalloproteinase-9 is a determinant of selective  
neurodegeneration. Neuron. 2014;81(2): 333-48. doi:10.1016/j.neuron.2013.12.009  
Kawanokuchi J, Mizuno T, Kato H, Mitsuma N, Suzumu ra A.  Effects of interferon-beta on microglial  
functions as inflammatory and antigen presen ting cells in the central nervous system.  
Neuropharmacol 2004;46(5):734-42 . 
Kithcart A, Cox GM, Sielecki T et al. A small-molecule inhibitor of macrophage migration inhibitory  
factor for the treatment of inflammatory disease.  Faseb J 2010;11:4459-66 . 
Kosutova P, Mikolka P, Kolomaznik M, Rezakova S, Calkovska A, Mokra D. Effects of roflumilast, a  
phosphodiesterase-4 inhibitor, on the lung functions  in a saline lavage-induced model of acute lung  
injury. Physiol Res 2017 Sep 22;66(Suppl.2):S237-S245 . 
Lai KN, Leung JC, Metz CN, Lai FM, Bucala R, La n HY. Role for macrophage migration inhibitory  
factor in acute respiratory distress syndrome. J Pathol 2003;199(4):496– 508. doi:10.1002/path.1291  
Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI, et al. The Glial Modulatory Drug  
AV411 attenuates mechanical allodynia in rat mode ls of neuropathic pain. Neuron Glia Biology  
(Pain special issue) 2007;2:279-91 . 
 
MediciNova Inc. 
Protocol MN-166-COVID-19-201 Amendment 4 
Confidential  
Page 44  of 44 
 Lee JY, Cho E, Ko YE, et al. Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity,  
protects agains ischemic brain injury in rats. Brain Res Brain Res. 2012;1431:97–106.  
doi:10.1016/j.brainres.2011.11.007  
Mizuno T, Kurotani T, Komatsu Y et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on  
neuronal cell death induced by activated microglia. Neuropharmacology 2004;46(3):404-11 . 
Nakamizo T, Kawamata J, Yoshida et al. Phosph odiesterase inhibitors are neuroprotective to cultured  
spinal motor neurons. J Neurosci Res 2003; 71:485-95 . 
Nishio Y, Koda M, Hashimoto M et al. Deletion of  macrophage migration inhibitory factor attenuates  
neuronal death and promotes functional recovery af ter compression-induced spinal cord injury in  
mice. Acta Neuropathol 2009;117(3):321-8 . 
Powell ND, Papenfuss TL, McClain MA et al. Cutting edge: macrophage migration inhibitory factor is  
necessary for progression of experimental autoimmune encephalomyelitis. J Immunol 2005 Nov  
1;175(9):5611–4 . 
Ranieri VM, Rubenfeld GD, Thompson BT, et al; ARDS Definition Task Force. Acute respiratory  
distress syndrome: the Berlin Definition. JAMA 2012; 307(23):2526-2533 . 
Suzumura A, Ito A, Yoshikawa M, Sawada M.  Ibudilast suppresses TNF-alpha production by glial cells  
functioning mainly as type III phosphodiesterase i nhibitor in the CNS. Brain Res 1999;837(1-2):203 -
12. 
Takuma K., Lee E., Enomoto R., Mori K., Baba A. and Matsuda T. (2001) Ibudilast attenuates astrocyte  
apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. British J Pharmacol  
2001;133:841–8 . 
Tominaga Y., Nakamura Y., Tsuji K., Shibata T. a nd Kataoka K. Ibudilast protects against neuronal  
damage induced by glutamate in cultured hippocampal neurons.  Clin Exper Pharmacol Physiol  
1996;23:519–523 . 
Wakita H, Tomimoto H, Akiguchi I, Lin JX, et al. Ibudilast, a phosphodiesterase inhibitor, protects  
against white matter damage under chronic cer ebral hypoperfusion in the rat. Brain Res 2003;  
992:53-59 . 
Yagi K, Tada Y, Kitazato KT, Tamura T, Satomi J, Nagahiro S. Ibudilast inhibits cerebral aneurysms by  
down-regulating inflammation-related molecules in the vascular wall of rats. Neurosurgery 2010  
Mar;66(3):551-9 . 
Yang D, Yang Y, Zhao Y. Ibudilast, a Phosphodiest erase-4 inhibitor, ameliorates Acute Respiratory  
Distress Syndrome in neonatal mice by allevi ating inflammation and a poptosis. Madi Sci Monit.  
2020; 26:e922281  
Yoshioka A., Shimizu Y., Hirose G., Kitasato H. and Pleasure D. Cyclic AMP-elevating agents prevent  
oligodendroglial excitotoxicity. J Neurochem 1998;70:2416–23 . 
Yoshioka A, Yamaya Y, Saiki S, Kanemoto M, Hirose G, Pleasure D.  Cyclic GMP/cyclic GMP -
dependent protein kinase system prevents excitotoxicity in an immortalized oligodendroglial cell  
line.  J Neurochem 2000;74(2):633-40 . 
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID -
19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar  
28;395(10229):1038] [published correction app ears in Lancet. 2020 Mar 28;395(10229):1038].  
Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3 .  
Page 1 of 13 
  
“Model” Informed Consent 
This is a “Model” informed consent provided  by MediciNova, Inc., only as a guide for 
the convenience of the Principal Investigator and the affiliated in stitution. It is the 
responsibility of each Investigator and institution to draft and obtain IRB/EC/REB 
approval of an Informed Consent that co mplies with Regulatory guidelines and 
ethical standards for their particular site. Any use, in whole or in part, of this 
“Model” Informed Consent shall be at the sole discretion of said Investigator and 
institution, and MediciNova, Inc., shall have no  liability for the form or content of the 
Informed Consent adopted for actual use by said Investigator and institution. 
 
Subject Information Sheet 
and Consent Form  
Protocol Number MN-166-COVID-19-201 
Protocol Title A Randomized, Double-Blind, Pl acebo-Controlled, Parallel 
Group Study to Evaluate the Safety, Tolerability, Biomarkers 
and PK of ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome (ARDS) 
Principal Investigator (Study Doctor)  
Sponsor MediciNova, Inc. 
4275 Executive Square 
Suite 300 La Jolla, CA 92037  
Sponsor Contact Kazuko Matsuda, MD, PhD, MPH 
Chief Medical Officer, MediciNova, Inc.  
(858) 373-1500 
Date 31 March 2021 
  
  
1 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 2 of 13 
  
 Invitation to  Partic ipate in a Research  Study  
You are being asked to participate in a research study because you  are at risk for developing Acute 
Respiratory Distress Syndrome, or ARDS . In order to decide whether or not to take part in this 
research study, you should know enough about its risks and benefits to make a decision. This 
process is called informed consent.  
The following information is provided in order to help you make an informed decision whether or not to participate in this study.  Please read this consent form carefully and take your time making your decision.  Please ask the study doctor or the study staff to explain any words or information that you do not clearly understand.  You will receive a copy of this signed and dated consent form to keep. For the purposes of this research, you will be referred to as a “participant .” 
It is expected that about 40 people will take part in this research study.  
MediciNova, Inc, a pharmaceutical company, is the sponsor of the study and is providing 
funding for the research study, including the study drug. 
XXX Hospital will be paid by the sponsor to conduct this research study.  
Purpose  of this  Research  Study  
You are being asked to take part in this Phase 2 research study t o evaluate the safety and 
tolerability  of ibudilast (also called MN -166) compared to placebo ( pills that looks like MN -166 
capsules but contain no active medicine).  Ibudilast is the investigational drug (study medication) being studied. ‘Investigational’ means that the drug has not been approved for treatment of any indication by the U.S. Food and Drug Administration (FDA).  
This is the first study to test ibudilast in subjects who have been diagnosed with COVID-19 and 
are at risk for developing ARDS.  
The study will be conducted at two study sites and approximately 40 subjects will be involved in 
this research study which will last for approximately 30 days in non- intubated patients and 60 
days in patients who are intubated days.  
The purpose of this study is to see if ibudilast can help prevent acute respiratory distress 
syndrome (ARDS), a serious lung injury in  patients who ar e diagnosed with COVID-19 and have 
an increased risk of developing ARDS such as: 
• Age greater  than 65 years old 
• Serious heart  disease  
• Chronic  lung  disease  
• Moderate to severe asthma  
• Diabetes,  and/or   
2 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 3 of 13 
 • Have a BMI  (body  mass  index)  at or greater than  40.  
 
Ibudilast has been approved in Japan for over 30 years for treatment of post- stroke dizziness and 
asthma. However , ibudilast has not been approved by the US Food and Drug Administration 
(FDA) for use in the US, Canada and Europe. This means that ibudilast can only be used in 
research studies. So far, this drug has been given to more than 750 people who have participated in clinical trials including healthy volunteers, people with diabetes who have nerve pain, and people with multiple sclerosis and amyotrophic latera l sclerosis (ALS) . 
 What should you know before you give consent? 
You are at risk for developing ARDS (acute respiratory distress syndrome) and  are now 
considering the use of ibudilast because y our doctor believes that ibudilast may help prevent it 
from oc curring.  
Before you consent to receiving treatment with ibudilast, you must be informed of the following: 
• In this study, you will receive standard of care and will have all the standard medications 
and procedures given for your condition. 
• Ibudilast is not  proven to prevent ARDS, therefore, there is no promise that your 
condition will not get worse;  
• You do not have to take this experimental drug and your decision about what to do must be made voluntarily. 
The experimental  drug, Ibudilast, has not received  approval for  use in  humans from  the U.S.  
Food and Drug  Administration  (FDA).  Research  studies to see how safe and how effective  this 
drug treats  diseases have been  conducted and future  clinical  trials  are possible. Your study doctor 
has agreed  to be the Principal Investigator , that is, they accept  the responsibilities  that come  
along with  treating  a patient  with  an experimental drug. These  responsibilities include, but are 
not limited  to, the following:  
• Carrying  out the research  study as described;  
 
• Monitoring you for  safety,  tolerability,  and changes in  your condition, if any, throughout 
the course of  treatment  and post- treatment;   
• Submitting  the necessary  documents to  the FDA,  Institutional Review  Board  (IRB),  and 
the sponsor throughout the  course of treatment  and follow-up.  
 
What will happen to  you during  the study?  
In order to enroll in the study, you will have to review  and sign  this Information and Informed 
Consent Form before having any study -specific procedures to  determine  if you are eligible  to 
participate.   
3 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 4 of 13 
 The study consists of a Screening  Phase,  a 7-day double- blind  Treatment  Phase and a Follow up 
Phase consisting of Day  14, Day  28 and Day  30 visits . Screening procedures may  be done over a 
3-day period. Study drug will be given  to you twice  a day (at  around breakfast  and dinner time)  
for 7 days. Two  days after  you finish  taking study drug, you will be  assessed  for clinical status 
and side effects.  At 30 days after  taking  study drug , you will have  a follow-up call  to see how 
you are doing. 
If you are eligible  to participate,  you will be randomized  to one of two  study drug treatments.  
“Study drug” used  in this consent form refers to  both MN-166 and placebo.  Being  randomized  
means that you are put in a group by a chance process,  like flipping a coin.  You  won't  know what  
group you are  in and neither will  your study doctor, study team  or sponsor. You  will have  a 1 out 
of 2 (or 50%) chance of being assigned  to the MN-166 group and 1 out of 2 (or 50%) chance of 
being assigned  to the placebo  group. The placebo  looks like  ibudilast but does not contain  the 
active drug.  Although you and your doctor will  not know which  study drug  you are receivi ng, 
this information  can be determined  in the event  of an  emergency.  
During the study, and after  signi ng the  Information  and Consent form,  the following procedures 
and assessments will  be done. 
Screening  Procedures: 
• Confirm that you are eligible to participate in the study 
• A physical exam will be done 
• Your clinical status will be assessed using a brief questionnaire  
• Your vital signs (blood pressure, heart rate, pulse, and temperature) will be taken 
• A 12 -lead ECG will be performed  
• Your oxygen use including CPAP, BiPAP, and nasal cannula will be assessed  
• A blood sample to collect biomarkers and routine clinical labs (complete blood 
count and comprehensive metabolic panel) will be taken from a needle in your arm 
for routine laboratory tests  and biomarkers (to measure inflammation in your body). 
The total amount of blood that will be taken will be about 2 tablespoons; 
• If you are a female of child -bearing potential , you will be given  a pregnancy  test; 
• You will be asked to report any prior medications taken within 7 days of starting the 
investigational drug; 
Upon review of all labs, t ests and clinical status, Dr. XXX or a designated study associate,  will 
speak with you about beginning participation in this research study. 
Treatment  Phase:  
Once you have been randomly assigned to receive either i budilast (MN -166) or placebo, the 
following assessments will be completed  on Study Days 1 through 7: 
4 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 5 of 13 
 • Ibudilast (MN -166) or placebo capsules will be given to you twice a day , once in 
the AM and once in the PM; 
• A physical exam will be done  
• Your oxygen use including CPAP, BiPAP, and nasal cannula will be measured;  
• Your clinical status will be assessed;  
• You will be asked questions about your general health; 
• You will be asked if there was a change in your medication(s). 
In addition, on Study Days 1, 3, 5 and 7, a 12-lead ECG will be done and a blood sample will be 
taken from a needle in your arm for routine, laboratory tests , biomarkers and pharmacokinetic 
samples to measure the amount of ibudilast in your blood. The total amount of blood that will be taken is estimated to be about 2 tablespoons (30 
CC). 
Study Day 14 
The following assessments will be completed on Study Day 14: 
• A physical exam will be done 
• Your clinical status will be assessed using a brief questionnaire  
• Your vital signs (blood pressure, heart rate, pulse, and temperature) will be taken 
• Your oxygen use including CPAP, BiPAP, and nasal cannula will be measured; 
• A blood sample to collect biomarkers and routine clinical labs (complete blood 
count and comprehensive metabolic panel) will be taken from a needle in your arm 
for routine laboratory tests and biomarkers (to measure inflammation in your body). 
The total amount of blood that will be taken will be about 2 tablespoons; 
• You will be asked questions about your general health and any medications you may 
have taken  
 
Study Day 28 
The following assessments will be completed on Study Day 28:  
• Your clinical status will be assessed using a brief questionnaire  
• Your oxygen use including CPAP, BiPAP, and nasal cannula will be measured;  
• You will be asked questions about your general health and any medications you may 
have taken  
 
Study Day 60 
5 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 6 of 13 
 The following assessments will be completed on Study Day 60: 
• Your clinical status will be assessed using a brief questionnaire  
• Your oxygen use including CPAP, BiPAP, and nasal cannula will be measured; 
• You will be asked questions about your general health and any medications you may 
have taken  
In addition, for subjects who are intubated (at screening or during the study the following w ill 
be done at Study Day 60: 
• Vital signs ( blood pressure, heart rate, pulse, and temperature) 
• 12-lead ECG   
• A blood sample will be taken for routine labs  
If you are discharged from the hospital early, you will be given your study medication with 
instructions to take at home. You will also be given a pulse oximeter, a device to measure your oxygen levels, once a day up to Day 14. You do not need to return the device.  
 
As a participant  in this study,  you have certain  responsibilities  to help  ensure your safety. 
These responsibilities are  listed  below:  
• Report all side effects and medical problems to the study  personnel; 
• Inform the study doctor or staff if you decide to discontinue your participation 
at which time you will be requested to complete the assessments that were scheduled  on the last day of study treatment.  
What are the risks associated with this study ? 
While participating in this  research study, you are at risk for side effects. Your study doctor will 
discuss these with you. The treatment used in this study may cause all, some, or none of the side effects listed. There also may be other side effects that have not been reported. Ot her drugs may 
be given to manage side effects and make you more comfortable (such as for nausea or headache). Many side effects go away shortly after the treatment is stopped, but in some cases side effects can be serious, or long -lasting.  
The known side effects are:  
Likely   (occurring in more than 20% of people taking the drug)   
• none  
Less Likely (occurring in less than 5% of people taking the drug)  
• appetite loss  
• nausea  
6 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 7 of 13 
 • diarrhea  
• headache  
• rash 
• itching  
Rare but serious (uncommon, between 1 -10 out of 1000 people who have taken MN-166) 
elevated liver enzymes which can be an indication of liver damage.  
Because this treatment is considered investigational and has not received FDA approval, there 
may be other risks that we do not know about at this time.  
 
Risk of Allergic Reaction  
As with any drug, an allergic reaction can occur. Allergic reactions can be mild or serious, which  
can even result in death in some cases. Common symptoms of an allergic reaction are rash, 
itching, skin problems, swelling of the face and throat, or trouble breathing. If you think you are having an allergic reaction or you are having trouble breathing, seek help from medical personnel right away.  
 
Number of Subjects who took Ibudilast  in Prior Clinical Trials  
Approximately 750 people, including nearly 300 with multiple sclerosis (another serious 
neurological disease), 130 with progressive MS and nearly 50 with early ALS (ALS history within 5 years) have been treated with MN-166 in research studies. Generally, good safety and tolerability have been seen. The side effects that were seen in a 2 -year study were gastrointestinal 
(meaning related to the stomach and intestines), and included nausea and diarrhea, and an increase in liver enzymes.   
MN-166 has been given to nearly 300 patients with relapsing remitting multiple sclerosis. There 
were 20 serious adverse events (side effects) reported. Most of the serious adverse events were 
gastrointestinal in nature or having to do with bone fractures. All of these serious adverse events 
were considered by the study doctors to be unlikely or not related to MN-166. Six of the serious adverse events were considered severe and two were considered life- threatening. Nine subjects 
stopped the study due to a side effect.  Two side effects (liver disorders) were possibly related to taking MN-166. 
MN-166 was given to approximately 130 patients with progressive multiple sclerosis. There 
were 58 serious adverse events (31 in placebo group, 27 in MN-166 group) reported.  Two 
serious adve rse events were considered possibly related to study treatment: thrombocytopenia in 
the placebo group and ataxia in the MN-166 group. 
MN-166 were given to nearly 50 subjects with early ALS patients (ALS history within 5 years). 
A total of 7 serious adverse events were reported in ALS patients. All of the serious adverse 
events were considered to be unlikely or unrelated to study drug by study doctor. Four of these 
7 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 8 of 13 
 serious events were considered severe (dysphagia, ureteral stone, pneumonia and ankle fracture) 
and bowel obstruction was considered life-threatening.  
As noted from the above- mentioned studies, gastrointestinal (GI) distress, which includes nausea 
and diarrhea, appears to be the most common side effect. The GI symptoms associated with MN -
166 tend to occur early (within 1 -2 weeks) and usually last for only a few days or weeks and then 
improve. These symptoms may be relieved with anti -diarrheal or anti -nausea drugs, if necessary. 
Usually, a majority of those receiving MN-166 recover from these symptoms within several days 
(with or without anti-diarrheal drugs). Talk to your study doctor if you experience these symptoms, particularly if they last for more than 2 -3 weeks.  
Other rare side effects associated with MN -166 are cold symptoms, itching sensation, rash, 
dizziness, tremors, insomnia (trouble sleeping), drowsiness, sudden blushing, anorexia (decreased appetite), abdominal pain, abdominal bloating, palpitations, flushed appearance, anemia (low red blood cell counts), low white blood cells, tirednes s, facial edema (swelling), 
abnormal sound sensitivity (changes in your hearing) and metallic taste in your mouth.     
Risks associated with blood drawing may include pain, bruising, and infection. Rarely, a person 
will faint.  
Reproductive Risks  
The effect of MN -166 on an embryo or fetus (developing baby still in the womb), or on a 
breastfeeding infant, is unknown and may be potentially harmful. Because of these unknown risks, if you are capable of giving birth to or fathering a child, you and your sexual partner should use adequate birth control measures while you are in this study. If you are a female who is sexually active and able to become pregnant, or a man with a sexual partner who is able to become pregnant, you must agree to use one or more of the birth control methods listed below. You must use birth control for the entire study and at least 30 days after your last dose of study drug. Acceptable birth control methods for this study are:  
• Abstinence (no sex)  
• Oral contraceptives (birth contr ol pills)  
• IUD (a small T -shaped device containing either copper or a hormone inserted into the 
womb for birth control) 
• Diaphragm with spermicide (a foam, cream or gel that kills sperm)  
• Norplant (birth control capsules that are inserted in the skin of the upper arm of a female)  
• Approved hormone injections 
• Condoms with spermicide 
•  
Women cannot take part in this study if they are: 
• Pregnant 
• Trying to become pregnant  
• Breastfeeding  
8 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 9 of 13 
  
If you are a menopausal woman and have not had a period for the past 12 months or more, you 
will not need to have a pregnancy test. Also, you will not need to have a pregnancy test if you have had a well -documented method of surgical sterilization (meaning hysterectomy or had your 
tubes tied/tubal ligation).  All other female subject s must have a negative pregnancy test before 
starting the study drug. 
If during the study you think you are pregnant, you must tell your study doctor and stop taking 
the study drug immediately. Your study doctor may ask you about the outcome of your pregnancy.  
Men cannot take part in this study if they are actively trying to get their sexual partner pregnant. 
During this study if you think your partner is pregnant you must tell the study doctor immediately. Your study doctor may ask you about the outcome of your partner’s pregnancy. 
What if there  are new  findings  about  the study  drug ? 
You will be told about any new information that might change your decision to take this 
experimental drug. 
 
What are the possible benefits of taking part in this study?  
There may be no direct clinical benefit from participating in this study. However, the information obtained from this study will be used by the Sponsor to determine the safety and tolerability of the study drug and may help in the future development of a new therapy for patients who are at risk for developing ARDS. 
 
What will it  cost  me to take  part  in this study ? 
The cost of the study drug will be paid for by the sponsor, MediciNova. The cost for some of your tests may  be billed to your insurance. 
 Can you choose to not participate or withdraw from the study without penalty or loss of benefits?  
Your participation in this study is completely voluntary. You may refuse to participate or withdraw from the study at any time. If you refuse to participate or withdraw from the study, you will not be penalized or lose any benefits and your decision will not affect your relationship with your doctor or hospital. 
9 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 10 of 13 
 However, if you decide to stop study participation, you are encouraged to talk with your doctor 
regarding safe removal from the study as described below.  If you must be discontinued from the 
study prior to its completion, you will be asked to have a final assessment  to evaluate your general 
health.  
What alternatives  are there if  I do  not want  to take the expe rimental drug?  
You do not have to participate in this study to receive treatment for your condition. The study 
doctor will discuss other treatment options with you,  including any potential side effects or risks. 
If you decide not to take part in this study it will not affect your ability to receive medical care.  
You will be treated as per standard of care.  
Does  my doctor need  my authorization  to use and disclose my  health  information ?  
Federal regulations give you certain rights related to your health information. These include the right to know who will be able to get the information and why they may be able to get it. Your doctor must get your authorization (permission) to use or give out any health information that might identify you. 
What about your confidentiality?    
Research records will be kept confidential to the extent allowed by law. The records of this study 
will be kept private.  In any kind of report published , we will not include any information that 
will make it possible to identify a patie nt. Under the terms specified in the Health Insurance 
Portability and Accountability Act of 1996 you have the right to privacy, and all information obtained in this clinical research study that can identify you will remain confidential to the greatest exte nt possible within state and federal laws.  Your name will not be revealed in any 
reports or publications resulting from this study.  The United States Food and Drug Administration (FDA), the Institutional Review Board (IRB), Sponsor and/or its designee (the study monitor), may inspect and copy your records pertaining to this study. The results of the study will be reported to the FDA and possibly other governmental agencies.  
When FDA requires subject names, FDA will treat such information as confidential;  however 
disclosure to third parties may be required on rare occasions.  Therefore, absolute protection of 
confidentiality by FDA cannot be promised or implied. Every effort will be made to keep your personal information confidential.  
 What will happen to the results of this clinical study?  
A description of this clinical trial will be available on http://www.ClinicalTrials.gov , as required 
by U.S. Law. This website will not include information that can identify you. At most, the w eb- 
site will include a sum mary of the results. You can search this w ebsite at any time.  
The results of this study will be used to make informed clinical decisions for developing this new study drug. If you want the results to be made available to you, please talk to the study doctor. Results from clinical studies are often published in scientific journals, however, your personal information will remain confidential.  
10 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 11 of 13 
  
Will you be  compensated  for participating  in this study?  
You will not be paid to participate in this research study. However, you will be reimbursed for 
travel expenses, if applicable, when accompanied by receipts. Your study coordinator will discuss 
this with you .  
Who  may use  and give out information  about  me? 
Information about your health may be used and given to others by your doctor and staff. This may include information obtained both during and after the experimental treatment. 
Who  might get this  information?  
Anyone working for or with your doctor may have access to your medical and experimental drug 
treatment information. 
Information about you and your health that might identify you may be given to: 
• The U.S. Food and Drug Administration (FDA) 
• Department of Health and Human Services (DHHS) agencies 
• Governmental agencies in other countries 
• The [ Name of Institutional Review Board ] 
• MediciNova, Inc. (sponsor) 
What if I decide not  to give permission  to use and give out  my health  information?  
By signing this consent form, you are giving permission to use and give out the health 
information listed above for the purposes described above. If you refuse to give permission, you will not be able to be treated with the experimental drug.  
 
May I review  or copy  the information  obtained from me  or created  about  me?  
You have the right to review and copy your health information.  
May I withdraw  or revoke (cancel)  my permission?  
Yes, but this permission will not stop automatically . You may withdraw or take away your 
permission to use and disclose your health information at any time. You do this by giving written 
notice to your doctor. If you withdraw your permission, you will not be able to continue taking the experimental drug. 
When you withdraw your permission, no new health information that might identify you will be 
gathered after that date. Information that has already been gathered may still be used and given to others.  
What happens  if I am  hurt  while  taking  Ibudilast ? 
If it is determined by Dr. Geoffrey Chupp that an injury occurred as a direct result of taking 
11 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 12 of 13 
 Ibudilast, then you and/or your insurance will not have to pay for the cost of immediate medical 
care to treat the injury.  
There are no plans to pay for any injury caused by the usual care you would normally receive for treating  your illness or the costs of any additional care. 
By signing this consent form, you will not give up any legal rights. 
Who  do I call if  I have questions  or concerns?  
Contact Dr. XXX at  XXX- XXX- XXXX , or Dr. Kazuko Matsuda, Chief Medical Officer at 
MediciNova (858-373-1500) for any of the following reasons: 
• If you have any questions concerning your participation in this study;   
• If at any time , you feel you have experienced a study- related  injury or a reaction to the 
experimental drug and for information about how to  receive treatment; or 
• If you have questions, concerns or complaints about the study  
If you have questions about your rights as a patient in this study or if you have questions, 
concerns or complaints about the study , you may contact:  
[Name, address and contact information of Institutional Review Board) 
Telephone:   
E-mail:   
[Name of IRB] is a group of people who independently review research, including single patient 
treatment plans.  
[Name of IRB] will not be able to answer some study-specific questions, such as questions about 
appointment times. However, you may contact [ Name of IRB] if your doctor or your doctor’s 
staff cannot be reached or if you wish to talk to someone other than your doctor or doctor’s staff.  
Do not sign this consent form unless you have had a chance to ask questions and have received satisfactory answers to all of yo ur questions. 
If you agree to participate in this study , you will receive a signed and dated copy of this consent 
form for your records. 
 
12 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
Page 13 of 13 
 CONSENT  
I have read the information in this consent (or it has been read to me). All my questions about 
this research study and my participation in it have been answered. I freely consent to participate 
in this research study. 
 I authorize the use and disclosure of my health information to the parties listed in the 
authorization section of this consent for the purposes described above.  
 By signing this consent form, I have not given up any of my legal rights.   ________________________________________ Print [Name of Patient]  
 
CONSENT SIGNATURES: 
  ________________________________________ __________________ Signature of Pa tient Date  
  ________________________________________ __________________ Signature of person obtaining consent Date  
   
_______________________________________________________________________ 
 
13 of 13 CONFIDENTIAL______________________________________________________________________________________________MN-166 oral capsule
______________________________________________________________________________________________
IND 149627 / Sequence No. 0006Protocol No. MN-166-COVID-19-201 (Amendment 4) - Model Informed Consent and Information SheetMediciNova Inc.
MediciNova Inc. 
Protoco l No: MN- 166-COVID- 19-20 I Statistical Analysis Plan Y2.0 
18 August 2022 
ST A TISTICAL ANALYSIS PLAN 
A Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study to Evaluate the 
Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics oflbudilast (MN-166) in 
COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome 
Authored 
bv: 
Reviewed 
bv: 
Contributor: 
Approved 
by: 
Date: MN-166-COVID-19-201 
Protocol Version: Amendment 2 (03 November 2020) 
Protocol Version: Amendment 4 (31 March 2021) 
Name Sie:nature 
Malath Makhay , PhD 
Director, Resea rch & 
Deve lopm ent 
MediciNova , Inc. 
Trina Wells ,J1-j-Data Scientist I 
MediciNova, Inc. 
Charles S Davis , PhD Date 
18-AUG-2022 
18-Aug-2022 
ddlr/J(fa/, Biostatistician Jf" /J IAj v 21/?2__ CSD Biostatistics , Inc 
Kazuko Matsuda , MD, 
PhD , MPH 
Chief Medical Officer 18-A UG-2022 
MediciNova, Inc. 
August 18, 2022 Version: 2.0 (replaces SAP vl.0) 
Confidentia l 
Page. 1 of 23 
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 2 of 23 
 HISTORY OF CHANGES  
All versions of the document must be documented in the table of history of changes. The 
owner of this document must act in accordance with the latest version of the document.  
Version   
Effective Date  
 Change description  
2.0 August 18, 2022 . Section 1 Introduction  
• Age range was corrected to reflect protocol.  
• Discrepancies between protocol and SAP was 
addressed  
. Section 2.2.3 Secondary Outcome Variables 
• Exploratory Analysis was described. 
. Section 6 Analysis Population 
• Full Analysis Set was corre cted 
. Section 10.1. Primary Eff icacy Variable Analysis  
• Nonresponders in the study were defined 
• A supportive analysis for each of the two co-
primary endpoints will be conducted. 
. Section 10.2 Secondary Efficacy Variable Analysis  
• Secondary endpoints that are defined as the change 
from baseline will be analyzed using analysis of 
covariance (ANCOVA) models  
1.0 May 18, 2022 None: Initial Document 
  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 3 of 23 
  
TABLE OF CONTENTS    
 
1 INTRODUCTION ........................................................................................................ 6  
2 STUDY OBJECTIVE AND ENDPOIINTS  .............................................................. 6  
2.1 Study Objectives .......................................................................................................... 6  
2.1.1  Primary objectives  ................................................................................................... 6  
2.1.2  Secondary Objectives  .............................................................................................. 6  
2.2 Study Endpoints (Outcome Variables) ........................................................................ 7  
2.2.1  Co-Primary Outcome Variable(s)  ........................................................................... 7  
2.2.2  Secondary Outcome Variable(s)  ............................................................................. 7  
2.2.3  Exploratory Endpoints ............................................................................................. 8  
3 STUDY METHODS AND ENDPOINTS  ................................................................... 8  
3.1 Overall Study Design and Plan .................................................................................... 8  
3.2 Selection of Study Population ...................................................................................... 8  
3.3 Method of Treatment Assignment and Randomization ............................................... 9  
3.4 Treatment Masking (Blinding)..................................................................................... 9  
4 SEQUENCE OF PLANNED ANALYSIS  .................................................................. 9  
4.1 Interim Analysis  ........................................................................................................... 9  
4.2 Data Monitoring Committee Meetings  ........................................................................ 9  
5 SAMPLE SIZE DETERMINATION  ......................................................................... 9  
6 ANALYSIS POPULATIONS  ...................................................................................... 9  
6.1 Use of analysis populations in different analyses ...................................................... 10  
7 GENERAL ISSUES FOR STATISTICAL ANALYSIS  ......................................... 10  
7.1 Definition of Treatment Arms  .................................................................................... 10  
7.2 Definition of Baseline  ................................................................................................ 10  
7.3 Definition of Visit Windows  ...................................................................................... 10  
7.4 Multicenter Study  ....................................................................................................... 10  
7.5 Multiple Comparisons and Multiplicity  ..................................................................... 11  
7.6 Planned Subgroup Analyses....................................................................................... 11  
7.7 Analysis Software ...................................................................................................... 11  
7.8 Clinical Status Scale ................................................................................................... 11  
8 STUDY PARTICIPANTS  ......................................................................................... 11  
8.1 Disposition of Participants and Withdrawals ............................................................. 11  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 4 of 23 
 8.2 Protocol Deviations .................................................................................................... 12  
8.3 Inclusion and Exclusion Criteria ................................................................................ 12  
9 DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS  .............. 12  
9.1 Demographics ............................................................................................................ 12  
9.2 Prior and Concomitant Medications .......................................................................... 12  
9.3 Baseline and Screening Conditions............................................................................ 13  
9.3.1  Baseline Medical History  ...................................................................................... 13  
10 EFFICACY ANALYSIS  ............................................................................................ 13  
10.1  Primary Efficacy Variable Analysis  .......................................................................... 13  
10.2  Secondary Efficacy Variable Analysis  ...................................................................... 14  
10.3  Exploratory Analysis.................................................................................................. 14  
10.4  Pharmacokinetics Analysis  ........................................................................................ 14  
10.4.1  Pharmacokinetic Samples  ...................................................................................... 14  
10.4.2  Pharmacokinetic Parameters  ................................................................................. 14  
11 SAFETY AND TOLERABILITY ANALYSIS  ....................................................... 15  
11.1  Adverse Events  .......................................................................................................... 15  
11.1.1  All Adverse Events  ................................................................................................ 16  
11.1.2  Adverse Events Leading to Withdrawal ................................................................ 16  
11.1.3  Serious Adverse Events ......................................................................................... 16  
11.1.4  Deaths  .................................................................................................................... 16  
11.2  Pregnancies  ................................................................................................................ 17  
11.3  Clinical Laboratory Evaluations ................................................................................ 17  
11.4  Electrocardiogram (ECG)  .......................................................................................... 17  
11.5  Vital Signs  .................................................................................................................. 17  
11.6  Physical examination  ................................................................................................. 17  
12 REFERENCES  ........................................................................................................... 18  
13 APPENDICES  ............................................................................................................ 19  
13.1  Schedule of Assessments (Amendment 2) ................................................................. 19  
13.2  Schedule of Assessments (Amendment 4) ................................................................. 20  
13.3  List of Tables  ............................................................................................................. 21  
13.4  List of Listings  ........................................................................................................... 23  
 
  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 5 of 23 
 ABBREVIATIONS  
 
Acronyms, 
Abbreviations, Initials  Description / Explanation  
AE Adverse Event  
ANOVA  analysis of variance  
BS Biostatistics  
Cfb Change from baseline  
CRF  Case Report Form  
CSR  Clinical Study Report  
FAS Full Analysis Set  
FDA  United States Food and Drug Administration  
GCP  Good Clinical Practice  
ICH The International Concil for Harmoni sation of Technical  
Requirements for Pharmaceuticals for Human Use  
IPF Idiopathic Pulmonary Fibrosis  
NA Not Applicable  
QA Quality Assurance  
QC Quality Control  
QOL  Quality of Life  
PM Project Manager  
PPS Per Protocl Set  
RA Regulatory Authority  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SAS Safety Analysis Set  
SOP Standard Operating Procedure  
TESAE  Treatment Emergent Serious Adverse Event  
TEAE  Treatment Emergent Adverse Event  
 
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 6 of 23 
 1 INTRODUCTION  
This Statistical Analysis Plan (SAP) describes the planned analysis and reporting 
MediciNova Inc. protocol MN -166- COVID -19-201, A Randomized, Double -Blind, 
Placebo -Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, 
Biomarkers and PK of ibudilast (MN -166) in COVID -19 Participants at Risk for Developing 
Acute Respiratory Distress Syndrome.  
This phase 2 study is being completed to assess the safety, tolerability, and efficacy of 
MN-166 in male and female subjects 18 to 80 years of age, inclusive, who are hospitalized 
for complications from COVID -19 infection, are at risk for developing ARDS, and receive 
standard of care including anticoagulation. The following documents were r eviewed in 
preparation of this SAP:  
• Clinical Study Protocol MN -166- COVID -19-201, amendment 2 issued 01 November 
2021 and amendment 4 issued 31 March 2021*  
• Case report forms (CRFs) for Protocol MN -166- COVID -19-201.  
• ICH E9: Guidance on Statistical Principles  for Clinical Trials.  
• ICH E3: Guideline for the format and content of the clinical and statistical sections of an application  
• ICH E14: Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs  
The SAP supplements the clinical protocol. Please refer to the clinical protocol for details on the rationale for the intervention, eligibility criteria, conduct of  the trial, clinical  
assessments and the timing  of their use in the trial, definitions and reporting  of adverse 
events, data management conventions, and regulatory oversight and compliance procedures. In case of discrepancies  between  the SAP and the clinical  protocol concerning 
matters of  data analysis,  the SAP is authoritative.  On all other matters,  the clinical protocol 
is authoritative.  
*No subjects were consented under  Protocol v .1.0, Amendment 1, and Amendment 3 because they were not 
submitted to the institutions ’ IRB.  
2 STUDY OBJECTIVE AND ENDPOIINTS  
2.1 Study Objectives  
2.1.1 Primary objectives  
The primary objectives of the study are to evaluate: 
• Efficacy of ibudilast vs. placebo in COVID-19 subjects measured by the proportion of subjects  free of respiratory failure at Day 7  
• Efficacy of ibudilast vs. placebo in COV ID-19 subjects measured by clinical status 
at Day 7  
2.1.2 Secondary Objectives  
The secondary objectives of the study are to evaluate:  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 7 of 23 
 • Efficacy of ibudilast vs. placebo in COVID-19 subjects measured by the proportion 
of subjects free of respiratory failure at Day s 14, 28 and 60 (in intubated subjects 
only)  
• Efficacy of ibudilast vs, placebo in COVID-19 subjects measured by clinical status     
at Days 14, 28 and Day 60 (in intubated subjects only) 
• Anti-inflammatory effects of ibudilast vs. placebo on cytokine levels 
• Safety and tolerability of ibudilast vs. placebo in COVID-19 subjects  
• Pharmacokinetics of ibudilast vs. placebo in COVID-19 subjects 
2.2 Study Endpoints (Outcome Variables)  
2.2.1 Co-Primary Outcome Variable(s)  
The co -primary objectives of the study will be evaluated based on the following clinical 
measures:  
• Proportion of subjects free from respiratory failure defined by free from supplemental oxygen requirements (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Day 7  
• Proportion of subjects with at least a one-point improvement in clinical status using 
the NIAID 8 -point ordinal scale and discharge record at Day 7 
2.2.2 Secondary Outcome Variable(s)  
• Proportion of subjects free from  respiratory failure as defined by free from 
supplemental oxygen requirement (invasive mechanical ventilation, non- invasive 
ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Days 14, 
28 and Day 60* 
• Propor tion of subjects with mechanical ventilation /intubation at Days 7, 14, 28 and 
Day 60* 
• Changes from baseline in clinical status using the NAID 8-point ordinal scale and discharged record at Days 7, 14, 28 and 60*  
• Proportion of subjects with at least a one-point improvement in clinical status using the NIAID 8 -point ordinal scale and discharge record at Days 14, 28 and 60* 
• All-cause mortality at Days 28and Day 60*  
• Proportion of the subjects discharged from hospital at Days 7, 14, 28 and 60*  
• Change from baseline in migration inhibitory factor (MIF), (interleukin 1- beta (IL -
1β), interleukin 6 (IL -6), tumor necrosis factor (TNF -α), and C -reactive protein 
(CRP) at Day 3,5,7 and 14 
• Incidence, frequency, and severity of adverse events at Day 7, 14, 28 and Day 60* 
• Change from baseline of the following parameters at Days 7, 14 and Day 60*: 
o ALT  
o AST  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 8 of 23 
 o Serum creatinine  
o BUN 
o Complete blood count 
o    Total bilirubin  
o D- dimer  
• PK plasma concentrations and parameter (PK population) 
 
*Intubated subjects only on Study Day 60  
2.2.3 Exploratory Endpoints 
Exploratory analysis not necessarily identified in this SAP may be performed to support the 
clinical development program. Any post-hoc or unplanned analysis not identified in this SAP performed will be clearly identified in the respective CSR.  
3 STUDY METHODS AND ENDPOINTS  
3.1 Overall Study Design and Plan  
This is a randomized (1:1), placebo-controlled, double-blind, parallel -group study of MN-166 
(ibudilast) in hospitalized COVID -19 subjects at risk for developing ARDS receiving 
standard of care including anticoagulation. Approximately 40 participants are planned to be enrolled. The study will consist of a Screening Phase followed by a 7- days Double -blind 
Treatment (DBT) and Follow -up Phase. Followi ng the Screening Phase, if the subject meets 
eligibility criteria, subject will be administered treatment with MN -166 (ibudilast) or placebo. 
Subjects will receive ibudilast 100 mg/d (50 mg b.i.d) or placebo every day for 7 days.  The Follow-up phase is consisted of three visits: Day 14, Day 28, and Day 60 (subjects enrolled under amendment 4 only) post- baseline visit.   
Subjects who are discharged prior to Day 7 will be given the remainder of their study medication to be taken at home and a pulse oximeter supplied by the sponsor to measure their O
2 levels once daily until Study Day 14. 
Eligible participants will consist of males and females ranging in age from 21 to 80 years old, inclusive, who have SARS-CoV-2 infection confirmed by WHO criteria, chest abnormalities consistent with COVID -19 pneumonia, SpO
2 ≤92% on room air, ≥ 24 BPM, and/or 
requirement of supplemental O 2.   
Overall study design and plan is described in detail in Protocol Section 11.  
3.2 Selection of Study Population 
Inclusion and exclusion criteria are described in detail in Final Protocol Sections 12.2 and 12.3. 
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 9 of 23 
 3.3 Method of Treatment Assignment and Randomization 
During the Double-blind Treatment Phase, randomization occurred in a 1:1 ratio (MN-166: 
Placebo). The randomization scheme was generated by an independent statistician and sent to each site’s unblinded pharmacist in a password protected file.  
3.4 Treatment Masking (Blinding)  
Participants and all personnel involved with the conduct and interpretation of the study, 
including the investigators, site personnel, and sponsor staff will be blinded to the treatment codes. Randomization data will be kept strictly confidential, filed securely by an appropriate group with the sponsor and accessible only to authorized persons (e.g., unblinded pharmacist) until the database is locked  
To ensure that treatment allocation remains concealed to both staff and participants, the following measures will be taken: 
• Active drug and placebo will be identical in appearance  
• Drug supplies to investigational pharmacy will be coded  
4  SEQUENCE OF PLANNED ANALYSIS  
4.1 Interim Analysis  
There are no planned interim analyses for this study. 
4.2 Data Monitoring Committee Meetings 
 Not applicable.  
5 SAMPLE SIZE DETERMINATION  
No prior data are available on which to base assumptions for sample size/power 
considerations. The results of this pilot study will be used to design future studies, and the sample size of approximately 40 participants is deemed to be appropriate for this purpose. 
6 ANALYSIS POPULATIONS  
The following analysis populations are planned for the studies: 
• Full Analysis Set (FAS) will include all randomized subjects.  
• Safety Analysis Set (SAS) will include all randomized subjects who received at least 
one dose of study drug and had at least one post- dose safety assessment.  
• Per Protocol Analysis (PP):  will consist of the FAS subjects excluding those with 
major protocol violations.  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 10 of 23 
 • Pharmacokinetic Population (PK): will consist of the subjects for which PK 
collection was performed. Eight subjects are anticipated to participate in PK sample 
collection.  
6.1 Use of analysis populations in different analyses 
Safety analyses will be conducted on the Safety Analysis Set, and participants will be 
analyzed based on the treatment they received. Efficacy analysis will be conducted on the Full Analysis Set, and participants will be analyzed based on the treatment to which they were randomly assigned. 
7 GENERAL ISSUES FOR STATISTICAL ANALYSIS  
Data from all clinical assessments will be listed and, where appropriate, summarized by 
treatment arms using descriptive statistics . Summary (descriptive) statistics of continuous 
variables include n, mean, standard deviation (SD), median, first quartile (Q1), third quartile (Q3), minimum and maximum values at each time -point. For categorical variables, the 
number and percent of counts will be presented.  
7.1 Definition of Treatment Arms  
Treatment arms will be denoted as follows in the TLFs:  
• “MN -166” - 50 mg of MN- 166 administered orally twice daily  
• “Placebo” – Matching Placebo administered orally twice daily  
7.2 Definition of Baseline  
Unless otherwise specified, baseline is defined as the measurement closest to the date of the 
first administration of Investigational Medicinal Product (IMP) and preceding the first dose of IMP (MN -166 or Placebo). 
7.3 Definition of Visit Windows  
The same visi t windows will be used as defined in the protocol.  
• Screening visit (up to - 3 days)  
• Day 1 (baseline) (0 days) 
• Days 2 -7 (0 days) 
• Day 14 (±3 days) 
• Day 28 (±3 days) 
• Day 60 (±7 days) 
7.4 Multi -center Study  
The study will be conducted at two centers:   
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 11 of 23 
 Denver Health and Hospital Authority 
Yale School of Medicine  
7.5 Multiple Comparisons and Multiplicity  
There are two co -primary endpoints. Because study success requires success on both, each 
will be tested using a  one-sided alpha level value of 0.025 (equivalent to a two-sided alpha of 
0.05). All other analyses will be conducted using one-sided tests at the alpha=0.025 level of 
significance, with no adjustment for multiplicity.  
7.6 Planned Subgroup Analyses  
No subgroup analyses are planned in this study. 
7.7 Analysis Software 
All analysis will be performed using SAS® Software version 9.4 or above.  
7.8 Clinical Status Scale  
In this trial, the National Institute of Allergy and Infectious Diseases (NIAID) 8 -point ordinal 
scale is utilized to assess clinical status at Screening, Days 1 -7, and on Days 14, 28, and 60 
(for intubated subjects only). In Section 14.5 of the protocol, the numbers (1- 8) are in reverse, 
where a higher number represents improvement, which is inconsistent wi th the official 
NIAID 8 -point ordinal scale. The SAS programmer will correct the NIAID 8-point ordinal 
scale to reflect the official scale shown below.  
1. Not hospitalized, no limitations on activities  
2. Not hospitalized, limitation on activities and/or requiring home oxygen 
3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing 
medical care  
4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID -19 related or otherwise) 
5. Hospitalized, requiring supplemental oxygen 
6. Hospitalized, on non-invasive ventilation or high flow oxygen devices 
7. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 
8. Death  
8 STUDY PARTICIPANTS  
8.1 Disposition of Participants and Withdrawals 
All participants who provide informed consent will be accounted for in this study. The 
number of screen failures will be presented. The number and proportion of participants in 
each analysis set will be presented by treatment arm (in percentage of the number  of 
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 12 of 23 
 participants randomly assigned) and overall. The number and proportion of completers will 
be presented by treatment arm and overall. The number and proportion of early withdrawals will be presented by the coded term for main reason of withdrawal and overall, by treatment arm and overall.  
Participants who are in the Safety Analysis Set but not in the Full Analysis Set will be listed. 
Randomization errors will be listed.  
8.2 Protocol Deviations 
The number and proportion of participants with protocol deviations will be presented by treatment arm, for each coded term.  
All protocol deviations will be listed.  
8.3 Inclusion and Exclusion Criteria  
Participants who meet all the inclusion criteria and none of the exclusion criteria are eligible to participate in the clinical trial.  
Deviations from inclusion/exclusion criteria will be listed.  
9 DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS  
9.1 Demographics  
For variables assumed to be continuous, like age at screening, body weight and height descriptive statistics will be prepared by treatment arm, for each analysis set separately.  
For categorical variables like gender, race, ethnicity, frequency tables (n a nd percentage) will 
be prepared by treatment arm, for each analysis set separately.  
All demography data will be listed. 
9.2 Prior and Concomitant Medications 
Prior medications/therapies are defined as those for which the end date is prior to the date of 
first IMP administration. Concomitant medications/therapies are defined as those with start date on or after the date of first IMP administration and those with start date prior to the first IMP use but with end date on or after the date of first IMP administration. 
Concomitant medications in the database will be coded using the most recent version of the 
World Health Organization Drug Dictionary which employs the Anatomical Therapeutic Chemical (ATC) classification system. The number and percentage of participan ts who took 
prior and concomitant medications will be summarized separately by ATC classification first level (alphabetically), ATC classification second level (in decreasing order of frequency) and treatment arm.  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 13 of 23 
 These therapeutics will be listed by subject along with their classification, indication of the 
treatment, total daily dose and start and stop date of the treatment. 
The number and percentage of participants who took prior and concomitant treatments will 
be presented separately.  
All prior and concomitant medication data will be listed.  
9.3 Baseline and Screening Conditions  
Baseline and Screening condition data will be assessed by treatment arm using descriptive statistics. No inferential test statistics are planned for baseline comparison of the tr eatment 
arms.  
9.3.1 Baseline Medical History  
All medical history records will be coded according to the latest version od MedDRA and summarized by system organ class and preferred term. The number and percentage of participants in different medical history categories will be presented by treatment arm.  
10 EFFICACY ANALYSIS  
Efficacy analysis will be performed on the Full Analysis Set. All efficacy measurements will be listed.  
10.1 Primary Efficacy Variable Analysis  
The co -primary efficacy endpoints are listed below.   Th e primary analysis for each of these 
two endpoints will be conducted  using Pearson’s chi- square tests. Because study success is 
defined as success on both, each of the two co-primary endpoints will be tested using a one-sided significance level of 0.025.  
• Proportion of subjects free from respiratory failure  
o Calculate the proportion of the subjects free from supplemental oxygen 
(invasive mechanical ventilation, non-invasive ventilation, high- flow 
oxygen, ECMO, CPAP, Bi PAP, nasal cannula) at Day 7  
• Proportion of subjects with improvement in clinical status using the NIAID 8-point ordinal scale and discharge record at Day 7  
o Calculate the proportion of the subjects who improved at least one-point from baseline  
For each of the two co -primary endpoints, subjects whose response status is unknown will 
be assumed to be nonresponders.  
A supportive analysis for each of the two co-primary endpoints will be conducted using the Mantel -Haenszel test stratified by the randomization stratification variable (use of IL-6 
antibody therapy). 
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 14 of 23 
 10.2 Secondary Efficacy Variable Analysis 
The secondary efficacy endpoints are the following: 
• Proportion of subjects free from  respiratory failure as defined by free from 
supplemental oxygen requirement (invasive mechanical ventilation, non- invasive 
ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Days14, 
28 and Day 60* Proport ion of subjects with mechanical ventilation /intubation at 
Days 7, 14, 28 and Day 60*  
• Change from baseline in clinical status using NIAID 8-point scale and discharge record at Days 7, 14, 28 and 60* Proportion of subjects with at least a one-point improve ment in clinical status using the NIAID 8 -point ordinal scale and discharge 
record at Day 14,28 and 60*  
• All-cause mortality at Days 28 and Day 60* Proportion of the subjects discharged 
from hospital at Day 7,14, 28 and 60*  
• Change from baseline in migration inhibitory factor (MIF), (interleukin 1- beta (IL -
1β), interleukin 6 (IL -6), tumor necrosis factor (TNF -α), and C -reactive protein 
(CRP) at Day 3, 5, 7 and 14  
*Intubated subjects only on Study Day 60  
All secondary endpoints that are defined as proportion variables will be analyzed using 
Pearson’s chi -square tests.   Secondary endpoints that are defined as the change from baseline 
will be analyzed using analysis of covariance (ANCOVA) models with treatment group as a factor and the baseline value of the corresponding endpoint as a covariate. All secondary analyses will be conducted using one-sided tests at the alpha=0.025 level of significance, with no adjustments for multiplicity.  
10.3 Exploratory Analysis  
Time to discharge  
10.4 Pharmacokinetics Analysis  
Pharmacokinetic analyses will be performed on plasma samples from eight subjects. Blood samples (approximately 2 mL per sample) will be collected at each time point for the bioanalytical assay of MN -166 and stored frozen at approximately - 80°C until shipment is 
sent to the PK vendor. Blood samples will be assayed for MN-166 using a validated liquid chromatography/tandem mass spectroscopy (LC/MS/MS) method. 
10.4.1 Pharmacokinetic Samples  
Pharmacokinetic samples will be collected on D ay 1: AM Predose, and at 2, 4, 8 and  
12 hours (Predose of PM dose), and on Day 3 and Day 5 at AM Predose.  
10.4.2 Pharmacokinetic Parameters  
The following PK parameters will be calculated using model-independent approaches (NCA) 
from MN -166 individual plasma concentrations, whenever practical.  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 15 of 23 
 Parameter  Description of Parameter  
tmax Time from the start of dosing at which the maximum concentration was observed  
Cmax Maximum observed concentration  
AUC 0-t Area under the concentration versus time curve from the start of dose administration to the 
last quantifiable point within the dosing interval  
λz Terminal rate constant calculated from the terminal slope of the log -linear regression of 
concentration with time  
t1/2 Terminal half -life, calculated as ln(2)/  λz 
AUC 0-∞ Area under the concentration versus time curve from time 0 to infinity calculated as AUC0 -t 
+ Clast/ ƛz, where Clast is the last quantifiable concentration  
CL or CL/F  Total body clearance, calculated as Dose/ AUC 0-( 
Vz or V z/F Terminal volume of distribution, calculated as CL/ λz 
11 SAFETY AND TOLERABILITY ANALYSIS  
All safety analyses will be performed for participants in the safety analysis set.  
The analysis of safety assessments in this study will include summaries of the following 
categories of safety and tolerability data collected for each subject:  
• Treatment Emergent Adverse Events:  
o Clinical laboratory Treatment Emergent Adverse Events 
o Discontinuation due to TEAEs 
o Treatment Emergent Serious Adverse Events  
• Pregnancies (if any reported)  
• Clinical Laboratory Investigations  
• Vital Signs  
• Physical examinations 
11.1 Adverse Events  
Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) central coding dictionary, version 25.0. 
The incidence of trea tment-emergent AEs (TEAEs, defined as AEs occurring from the time 
of first dose through 7 days after the last dose of MN-166), SAEs and AEs leading to 
discontinuations will be summarized by treatment group. Incidence of TEAEs will also be summarized by sev erity (mild, moderate, or severe), as well as by relationship to treatment 
(not related, possibly related, or probably related) and by seriousness. If it cannot be determined whether the AE is treatment emergent due to a partial onset date then it will be counted as such.  
Summaries that are displayed by system organ class and preferred terms will be ordered by descending order of incidence of system organ class and preferred term within each system organ class.  Summaries of the following types will be pre sented:  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 16 of 23 
 • Subject incidence of TEAEs and total number of unique TEAEs by MedDRA system 
organ class and preferred term.   
• Subject incidence of TEAEs by MedDRA system organ class, preferred term, and 
highest severity.  At each level of subject summarization, a subject is classified according to the highest severity if the subject reported one or more events.  AEs with missing severity will be considered severe for this summary. 
• Subject incidence of TEAEs by MedDRA system organ class, preferred term, and closest  relationship to study drug (Related/Not Related).  At each level of subject 
summarization, a subject is classified according to the closest relationship if the subject reported one or more events.  AEs with a missing relationship will be considered related for this summary. 
• Subject incidence of serious TEAEs and total number of unique serious TEAEs by MedDRA system organ class and preferred term.   
• Subject incidence of TEAEs leading to study discontinuation or death by MedDRA system organ class and preferred term.   
As this is a double-blind study, the causality assessment should be made under the 
assumption that the subject is receiving active study medication. If considering unblinding, this assessment should be made prior to unblinding to avoid bias. 
11.1.1 All Adverse Events  
An overview of number of participants (%) with treatment- emergent AEs will be presented 
for the main AE categories (All AEs, AEs leading to discontinuation, SAEs, SAEs leading to 
discontinuation, AEs with at least Grade 3 severity (Severe A Es, Life -threatening AEs, 
Deaths), AEs and SAEs with relationship to IMP as possibly related, probably related, or related) by treatment arm and phase.  
11.1.2 Adverse Events Leading to Withdrawal 
A data listing of AEs leading to withdrawal will be provided, displaying details of the event(s) captured on the CRF. 
11.1.3 Serious Adverse Events  
A data listing of SAEs will be provided, displaying details of the event(s) captured on the 
CRF. Serious adverse event narratives will be provided for the CSR by MediciNova.  
11.1.4 Deaths  
If any subject dies during the study, relevant information will be supplied in a data listing, 
and appropriate SAE narratives. 
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 17 of 23 
 11.2 Pregnancies  
Pregnancy data will be shown in a data listing. No special analysis will be performed on the 
pregnancy data. Participants are to be discontinued from the study if they become pregnant. 
11.3 Clinical Laboratory Evaluations 
Changes from baseline in laboratory values will be summarized by treatment groups for 
continuous variables. Lab shift tables showing incidence of new or worsening clinically significant findings from baseline to the last visit will be displayed by treatment groups. Shift from baseline to the highest lab value, and from baseline to the lowest lab value will also be displayed. Incidence of out-of-normal-range values and markedly abnormal change from 
baseline in laboratory safety test variables will be tabulated by treatment group.  Baseline is defined as the last non-missing value prior to the start of study drug infusion. 
11.4 Electrocardiogram (ECG)  
Descriptive statistics will be presented for ECG measures of PR interval, QRSD interval, QT 
interval, QTc interval (Fridericia’s method), and HR. These statistics will be presented by treatment arm, phase and visit.  
The number and percentage of subjects with normal and abnormal ECG results will be summarized by treatment arm, phase, and visit. All ECG measurements will be listed.  
11.5 Vital Signs  
Changes in vital signs from baseline to each visit will be summarized by treatment groups.  
11.6 Physical examin ation  
Physical examination results will be included in data listings only.  
  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 18 of 23 
 12 REFERENCES  
1. International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals  for Human  Use, ICH  Harmonised  Tripartite  
Guideline, Statistical Principles  for Clinical Trials (E9), 5 February 1998. 
2. International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals  for Human  Use, ICH  Harmonised  Tripartite  
Guideline, Structure  and Content of Clinical Study Reports (E3), 30 November 
1995. 
3. Gibaldi M, Perrier  D. Pharmacokinetics.  2nd ed. New  York, NY: Marcel  Dekker; 1982.  
4. Gough K, Hutchinson M, Keene O, Byrom B, Ellis S, Lacey L et al. Assessment of 
dose proportionality: Report  from  the Statisticians  in the Pharmaceutical  
Industry/Pharmacokinetics UK joint working party. Drug Information Journal 1995; 
29: 1039-1048. 
5. Emergent Product Development Gaithersburg Inc. Randomized, double-blind, placebo-
controlled, parallel group, single ascending dose study to determine the safety, 
tolerability and pharmacokinetics of UV-4B solution administered  orally  in healthy  
subjects.  Clinical Report for Study ID 13-0001 issued  07 July 2016.  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 19 of 23 
 13 APPENDICES  
13.1 Schedule of Assessments (Amendment 2)  
 
 
   
   Phase  Screening  Double -Blind Treatment Phase d,f     Follow -up  
Study Day  
 Day -3 Day 1  
BL Day 
2 Day 
3 Day 
4 Day 
5 Day 
6 Day 
7 Day 14d 
 (± 3)  Day 28   
(+/-3)  
Informed consent  X          
Inclusion/exclusion 
criteria review  X          
 Brief physical exam  X X  X  X  X X  
Clinical status using 
NIAID scale  X X X X X X X X X X 
Vital signs (BP, RR,  
HR, Temp)  X X X X X X X X X  
O2 therapy status  
and SpO 2 X X X X X X X X X  
12-lead ECG  X Xa  Xa  Xa  Xa   
Biomarker plasma 
samples: MIF, IL-1 β,  
IL-6, TNF -α X X  
 X  X  X X  
PK blood sampleb  X  X  X     
CBC, CMP, CRP,  
D-dimer, PT, INR  Xc X  X  X  X X  
Randomizee X          
Administer study 
drug   X X X X X X X   
Adverse event review   X X X X X X X X  
Prior/Concomitant 
medication review  X X X X X X X X X  
Record survival 
status           X 
 
 a 12-lead ECG to be done between 2 -4 hours after AM dose.   
b Collect PK samples on Day 1 in the AM prior to study drug dosing and at 2, 4, 8, and 12 hours (Predose of PM dose); Day 3 and  
   Day 5 prior to AM study drug dosing. PK samples to be collected for 8 subjects only.      
c Serum β -hCG for pre -menopausal wo men.  
d Telephone follow -up if subject is not in hospital. If subject is no longer hospitalized or cannot return due to COVID restrictions,  
a telephone follow -up to record O 2 usage/levels, AEs and conmeds may be conducted. All other assessments are optional.  
e Subjects may be randomized during the Screening Phase after all of the screening assessments are completed and subject is  
   considered eligible for the study or on Day  1.  
f If subject prematurely discontinues from the study or is discharged from the hospital on Days 2, 4, or 6 collect biomarker sa mples in  
addition to other scheduled assessments. If subject prematurely discontinues from the study or is discharged on Days 1, 3, 5, or 7,  
conduct the study assessments scheduled on those days.  
gThirty -one (31) subjects were consented under Protocol amendment 2.  
 
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 20 of 23 
 13.2  Schedule of Assessments (Amendment 4)  
 
 Phase  Screening  Double -Blind Treatment Phase e,g  Follow -up 
Study Day  
 Day -3 Day 1  
BL Day 
2 Day 
3 Day 
4 Day 
5 Day 
6 Day 
7  
Day 14e 
(± 3)   
Day 28 
(±3) Day 60  
(±7) 
Informed consent  X           
Inclusion/exclusion 
criteria review  X           
 Brief physical exam  X X  X  X  X X   
Clinical status 
using NIAID scale  X X X X X X X X X X X 
Vital signs (BP, 
RR,  
HR, Temp)  X X X X X X X X X  Xi 
O2 therapy status 
and SpO 2 X X X X X X X X X X X 
12-lead ECG  X Xa  Xa  Xa  Xa   Xi 
Biomarker plasma 
samples: MIF, IL-
1β, IL-6, TNF -α Xb X  
 X  X  X X   
PK blood samplec  X  X  X      
CBC, CMP, CRP,  
D-dimer, PT, INR  Xd X  X  X  X X  Xi 
Randomize f X           
Administer study 
drug   X h X X X X X X    
Adverse event 
review   X X X X X X X X X X 
Prior/Concomitant 
medication review  X X X X X X X X X X X 
Record survival 
statusj         X X X 
a 12-lead ECG to be done between 2 -4 hours after AM dose.   
b Biomarker blood sample collection at screening is optional if Screening and Day 1 assessments occur on the same day.  
c Collect PK samples on Day 1 in the AM prior to study drug dosing and at 2, 4, 8, and 12 hours (Predose of PM dose); Day 3  
  and Day 5 prior to AM study drug dosing. PK samples to be collected for 8 subjects only.      
d Serum β -hCG for pre -menopausal women.  
e Telephone follow -up if subject is not in hospital. If subject is no longer hospitalized or cannot return due to COVID restrictions,  
a telephone follow -up to record O 2 usage/levels, AEs and conmeds may be conducted. All other assessments are optional.  
f Subjects may be randomized during the Screening Phase after all of the screening assessments are completed and subject i s  
   considered eligible for the study or on Day 1.  
g If subject prematurely discontinues from the study or is discharged from the hospital on Days 2, 4, or 6 collect biomarkers  
   samples in addition to other scheduled assessments. If subject prematurely discontinues from the study or is discharged on Days 1, 3, 5, or 7,  
conduct the study assessments scheduled on those days.  
h The first dose of study drug may be started in the AM or the PM.  
  i  Vital signs, ECG and safety labs will be done in intubated subjects only.   
j Survival status is captured on the NIAID questionnaire.  
kFive (5) subjects were consented under Amendment 4.  
 
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 21 of 23 
 13.3 List of Tables  
 
Table 
Number  Table Description  
14.1 Demographic Data  
14.1.1  Subject Disposition (including discontinued subjects)  
14.1.2  Summary of Protocol Deviations  
14.1.3  Demographics and Baseline Characteristics  
 Summary of Disease Characteristics at Baseline by Treatment  
14.1.4  Summary of Medical History  
14.1.5  Prior and Concomitant Medications (Safety Population)  
14.1.6  Study Drug Exposure  
14.2 Efficacy  
14.2.1  Number (%) of subjects free from respiratory failure at Day 7  
14.2.2  Number (%) of subjects with at least a 1 -point improvement in clinical status using the NIAID 8 -point 
ordinal scale at Day 7  
14.2.3  Number (%) of subjects free from respiratory failure at Days 14, 28, and 60  
14.2.4  Number (%) of subjects with mechanical ventilation/i ntubation at Days 7, 14, 28, and 60  
14.2.5  Change from baseline in clinical status using the NIAID 8 -point ordinal scale at Days 7, 14, 28, and 60  
14.2.6  Number (%) of subjects with at least a 1 -point improvement in clinical status using the NIAID 8-point 
ordinal scale at Days 14, 28, and 60  
14.2.7  Number (%) of subjects discharged from hospital at Days 7, 14, 28, and 60  
14.2.8  All-cause mortality at Days 28 and 60  
14.3 Safety  
14.3.1  Summary of Treatment -emergent adverse events by Treatment  
 14.3.1.1  Incidence of TEAEs MedDRA System Organ Class and Preferred Term by Treatment  
14.3.1.2  Incidence of TEAEs Occurring in more than 5% of Subjects by Treatment  
14.3.1.3  Incidence of Post -treatment AEs by Treatment  
14.3.1.4  Incidence of TEAEs by MedDRA System Organ Class, Preferred Term and Severity  
14.3.1.5  Incidence of Treatment -Emergent Adverse Events by MedDRA System Organ Class, Preferred Term and 
Relationship to Study Drug  
14.3.1.6  Incidence of Treatment -Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, 
Relationship to Study Drug, and Severity  
14.3.2  Incidence of Serious Treatment -Emergent Adverse Events by MedDRA System Organ  Class and Preferred 
Term  
14.3.3  Incidence of Serious Treatment -Emergent Adverse Events by MedDRA System Organ Class, Preferred 
Term and Severity  
14.3.4  Incidence of Serious Treatment -Emergent Adverse Events by MedDRA System Organ Class,  Preferred 
Term and Severity  
14.3.4.1   Incidence of Subjects with Serious Treatment -Emergent Adverse Events by MedDRA System Organ Class, 
Preferred Term and Relationship  
14.3.4.2  Incidence of Serious Treatment -Emergent Adverse Events by MedDRA System Organ Class, Preferred 
Term and Relationship  
14.3.4.3  Incidence of Serious Treatment -Emergent Adverse Events by MedDRA System Organ Class, Preferred 
Term, Relationship and Severity  
14.3.4.4  Incidence of TEAEs Leading to Early Termination by Treatm ent 
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 22 of 23 
 14.3.4.5  Incidence of Deaths by Treatment  
14.3.4.6  Incidence of TEAEs by Maximum Severity by Treatment  
14.3.4.7  Summary of Clinical Laboratory Data: Clinical Chemistry by Treatment  
14.3.4.8  Summary of Clinical Laboratory Data: Clinical Hematology by Treatment  
14.3.4.9  Shifts from Baseline of Clinical Laboratory Data: Clinical Chemistry – Shift from Baseline to the Last Visit  
14.3.4.10  Shifts from Baseline of Clinical Laboratory Data: Clinical Hematology by Treatment  
 
  
MediciNova Inc.   Statistical Analysis Plan V2.0  
Protocol No: MN -166-COVID- 19-201  18 August 2022  
 
Confidential  
  
 Page: 23 of 23 
 13.4 List of Listings  
Listing 
Number  Listing Description  
16.2 Subject Data Listings  
16.2.1  Analysis Populations and Treatment  
16.2.1.1  Subject Disposition  
16.2.1.2  Inclusion/Exclusion Criteria  
16.2.2  Protocol Deviations  
16.2.2.1  Major and Minor Protocol Deviations  
16.2.2.3  Randomization Errors  
16.2.3.1  Demographics and Other Baseline Characteristics  
16.2.4  Prior, Concomitant, and Post -treatment Medications  
16.2.4.1  Medical History  
16.2.5  Study Drug Exposure  
16.2.5.1  Drug Accountability and Compliance  
16.2.5.2  Investigator Dose Optimization  
14.2.5.3  Dose Interruptions  
16.2.6  Individual Response Efficacy  
16.2.6.1  NIAID clinical status 8 -point ordinal scale  
16.2.6.2  O2 assessment including invasive mechanical ventilation, non -invasive ventilation (CPAP, 
BiPAP, nasal cannula high -flow oxygen), or ECMO and SpO2 
16.2.6.3  Day of Hospital Discharge  
16.2.6.4  Survival Status  
16.2.7  Individual Safety  
16.2.7.1  Adverse Events  
16.2.7.2  Serious Adverse Events  
16.2.7.3  Adverse Events Leading to Early Termination  
16.2.7.4  Listing of Deaths  
16.2.8  Listing of Individual Laboratory Measurements by Subject, when Required by Regulatory 
Authorities  
16.2.8.1  Clinical Laboratory Data: Chemistry  
16.2.8.2  Clinical Laboratory Data: Hematology  
16.2.8.3  Pregnancy Tests  
16.2.8.4  Vital Signs  
16.2.8.5  Electrocardiogram, Site Interpretation  
16.2.8.6  Electrocardiogram, Central Reader Interpretation  
16.2.8.7  Physical Examination  
 